<!DOCTYPE html>
<html class="no-js" lang="en" dir="ltr" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:dc="http://purl.org/dc/terms/" xmlns:foaf="http://xmlns.com/foaf/0.1/" xmlns:rdfs="http://www.w3.org/2000/01/rdf-schema#" xmlns:sioc="http://rdfs.org/sioc/ns#" xmlns:sioct="http://rdfs.org/sioc/types#" xmlns:skos="http://www.w3.org/2004/02/skos/core#" xmlns:xsd="http://www.w3.org/2001/XMLSchema#" xmlns:schema="http://schema.org/" xmlns:fb="http://ogp.me/ns/fb#">

<head>
  <!-- Set gtm id codes for various environments. -->

	<!-- Google Tag Manager -->
	<script>(function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start':
	new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0],
	j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';j.async=true;j.src=
	'https://www.googletagmanager.com/gtm.js?id='+i+dl;f.parentNode.insertBefore(j,f);
	})(window,document,'script','dataLayer','GTM-W3ZV');</script>
	<!-- End Google Tag Manager -->
  <meta charset="utf-8">
    <title>Centre for Drug Development: Strategy and portfolio | Cancer Research UK</title>

  <script charset="UTF-8" src="//cdn.cookielaw.org/scripttemplates/otSDKStub.js" data-domain-script="81232513-709c-4b95-8a41-a4b812c22fdc" async=""></script>
<meta http-equiv="Content-Type" content="text/html; charset=utf-8">
<link rel="shortcut icon" href="https://www.cancerresearchuk.org/sites/all/themes/custom/cruk/favicons/favicon.ico">
<link href="/sites/all/themes/custom/cruk/fonts/cruk-icons/CRUKIcons.woff" rel="preload" as="font" crossorigin="1">
<link href="/sites/all/themes/custom/cruk/fonts/museo/MuseoSansRounded-700.woff2" rel="preload" as="font" crossorigin="1">
<link href="/sites/all/themes/custom/cruk/fonts/museo/MuseoSansRounded-500.woff2" rel="preload" as="font" crossorigin="1">
<link href="/sites/all/themes/custom/cruk/fonts/museo/MuseoSans-500.woff2" rel="preload" as="font" crossorigin="1">
<link href="/sites/all/themes/custom/cruk/fonts/progress/Progress-Regular.woff" rel="preload" as="font" crossorigin="1">
<link href="/sites/all/themes/custom/cruk/fonts/Poppins-Regular.woff2" rel="preload" as="font" crossorigin="1">
<link rel="alternate" href="https://www.cancerresearchuk.org/funding-for-researchers/our-research-infrastructure/our-centre-for-drug-development/centre-for-drug-development-strategy-and-portfolio" hreflang="en-gb">
<script>{
    "@context": "https://schema.org",
    "@graph": [
        {
            "@type": "Organization",
            "additionalType": "NGO",
            "@id": "https://www.cancerresearchuk.org",
            "name": "Cancer Research UK",
            "address": {
                "@type": "PostalAddress",
                "streetAddress": "2 Redman Place",
                "addressRegion": "London",
                "postalCode": "E20 1JQ",
                "addressCountry": "UK"
            },
            "telephone": "03001234452",
            "url": "https://www.cancerresearchuk.org/",
            "sameAs": [
                "https://en.wikipedia.org/wiki/Cancer_Research_UK",
                "https://www.youtube.com/cancerresearchuk",
                "https://en-gb.facebook.com/cancerresearchuk",
                "https://twitter.com/CR_UK",
                "https://www.instagram.com/cr_uk",
                "https://www.linkedin.com/company/cancer-research-uk"
            ],
            "image": {
                "@type": "ImageObject",
                "url": "https://www.cancerresearchuk.org/sites/all/themes/custom/cruk/cruk-logo.svg"
            },
            "logo": {
                "@type": "ImageObject",
                "representativeOfPage": "True",
                "url": "https://www.cancerresearchuk.org/sites/all/themes/custom/cruk/cruk-logo.svg"
            }
        }
    ]
}</script>
<meta name="robots" content="follow, index">
<link rel="canonical" href="https://www.cancerresearchuk.org/funding-for-researchers/our-research-infrastructure/our-centre-for-drug-development/centre-for-drug-development-strategy-and-portfolio">
<link rel="shortlink" href="https://www.cancerresearchuk.org/node/190976">
<meta property="og:site_name" content="Cancer Research UK">
<meta property="og:type" content="article">
<meta property="og:title" content="Centre for Drug Development: Strategy and portfolio">
<meta property="og:url" content="https://www.cancerresearchuk.org/funding-for-researchers/our-research-infrastructure/our-centre-for-drug-development/centre-for-drug-development-strategy-and-portfolio">
<meta property="og:updated_time" content="2025-01-24T11:17:12+00:00">
<meta name="twitter:card" content="summary">
<meta name="twitter:url" content="https://www.cancerresearchuk.org/funding-for-researchers/our-research-infrastructure/our-centre-for-drug-development/centre-for-drug-development-strategy-and-portfolio">
<meta name="twitter:title" content="Centre for Drug Development: Strategy and portfolio">
<meta property="article:published_time" content="2017-02-14T14:13:16+00:00">
<meta property="article:modified_time" content="2025-01-24T11:17:12+00:00">

      <link rel="apple-touch-icon" sizes="57x57" href="https://www.cancerresearchuk.org/sites/all/themes/custom/cruk/favicons/apple-touch-icon-57x57.png">
<link rel="apple-touch-icon" sizes="60x60" href="https://www.cancerresearchuk.org/sites/all/themes/custom/cruk/favicons/apple-touch-icon-60x60.png">
<link rel="apple-touch-icon" sizes="72x72" href="https://www.cancerresearchuk.org/sites/all/themes/custom/cruk/favicons/apple-touch-icon-72x72.png">
<link rel="apple-touch-icon" sizes="76x76" href="https://www.cancerresearchuk.org/sites/all/themes/custom/cruk/favicons/apple-touch-icon-76x76.png">
<link rel="apple-touch-icon" sizes="114x114" href="https://www.cancerresearchuk.org/sites/all/themes/custom/cruk/favicons/apple-touch-icon-114x114.png">
<link rel="apple-touch-icon" sizes="120x120" href="https://www.cancerresearchuk.org/sites/all/themes/custom/cruk/favicons/apple-touch-icon-120x120.png">
<link rel="apple-touch-icon" sizes="144x144" href="https://www.cancerresearchuk.org/sites/all/themes/custom/cruk/favicons/apple-touch-icon-144x144.png">
<link rel="apple-touch-icon" sizes="60x60" href="https://www.cancerresearchuk.org/sites/all/themes/custom/cruk/favicons/apple-touch-icon-152x152.png">
<link rel="apple-touch-icon" sizes="60x60" href="https://www.cancerresearchuk.org/sites/all/themes/custom/cruk/favicons/apple-touch-icon-180x180.png">
<link rel="icon" type="image/png" href="https://www.cancerresearchuk.org/sites/all/themes/custom/cruk/favicons/favicon-32x32.png" sizes="32x32">
<link rel="icon" type="image/png" href="https://www.cancerresearchuk.org/sites/all/themes/custom/cruk/favicons/favicon-194x194.png" sizes="194x194">
<link rel="icon" type="image/png" href="https://www.cancerresearchuk.org/sites/all/themes/custom/cruk/favicons/favicon-32x32.png" sizes="96x96">
<link rel="icon" type="image/png" href="https://www.cancerresearchuk.org/sites/all/themes/custom/cruk/favicons/android-chrome-192x192.png" sizes="192x192">
<meta name="theme-color" content="#ffffff">
<link rel="icon" type="image/png" href="https://www.cancerresearchuk.org/sites/all/themes/custom/cruk/favicons/favicon-16x16.png" sizes="16x16">
<link rel="manifest" href="https://www.cancerresearchuk.org/sites/all/themes/custom/cruk/favicons/manifest.json">
<link rel="shortcut icon" href="https://www.cancerresearchuk.org/sites/all/themes/custom/cruk/favicons/favicon.ico">
<meta name="msapplication-TileImage" content="https://www.cancerresearchuk.org/sites/all/themes/custom/cruk/favicons/mstile-144x144.png">
<meta name="msapplication-TileColor" content="#ec008c">
<meta name="msapplication-config" content="https://www.cancerresearchuk.org/sites/all/themes/custom/cruk/favicons/favicons/browserconfig.xml">
<meta name="apple-mobile-web-app-title" content="CRUK">
<meta name="application-name" content="CRUK">
  
  <meta http-equiv="X-UA-Compatible" content="IE=edge,chrome=1">
  <meta http-equiv="cleartype" content="on">
  <meta name="viewport" content="width=device-width, initial-scale=1">

  <style>
@import url("https://www.cancerresearchuk.org/modules/system/system.base.css?");
@import url("https://www.cancerresearchuk.org/modules/system/system.menus.css?");
@import url("https://www.cancerresearchuk.org/modules/system/system.messages.css?");
@import url("https://www.cancerresearchuk.org/modules/system/system.theme.css?");
</style>
<style>@font-face{font-family:"MuseoSansRounded-500";font-display:swap;src:url("/sites/all/themes/custom/cruk/fonts/museo/MuseoSansRounded-500.eot");src:url("/sites/all/themes/custom/cruk/fonts/museo/MuseoSansRounded-500.eot?#iefix") format("embedded-opentype"),url("/sites/all/themes/custom/cruk/fonts/museo/MuseoSansRounded-500.woff2") format("woff2"),url("/sites/all/themes/custom/cruk/fonts/museo/MuseoSansRounded-500.woff") format("woff"),url("/sites/all/themes/custom/cruk/fonts/museo/MuseoSansRounded-500.ttf") format("truetype")}@font-face{font-family:"MuseoSansRounded-700";font-display:swap;src:url("/sites/all/themes/custom/cruk/fonts/museo/MuseoSansRounded-700.eot");src:url("/sites/all/themes/custom/cruk/fonts/museo/MuseoSansRounded-700.eot?#iefix") format("embedded-opentype"),url("/sites/all/themes/custom/cruk/fonts/museo/MuseoSansRounded-700.woff2") format("woff2"),url("/sites/all/themes/custom/cruk/fonts/museo/MuseoSansRounded-700.woff") format("woff"),url("/sites/all/themes/custom/cruk/fonts/museo/MuseoSansRounded-700.ttf") format("truetype")}@font-face{font-family:"MuseoSans-500";font-display:swap;src:url("/sites/all/themes/custom/cruk/fonts/museo/MuseoSans-500.eot");src:url("/sites/all/themes/custom/cruk/fonts/museo/MuseoSans-500.eot?#iefix") format("embedded-opentype"),url("/sites/all/themes/custom/cruk/fonts/museo/MuseoSans-500.woff2") format("woff2"),url("/sites/all/themes/custom/cruk/fonts/museo/MuseoSans-500.woff") format("woff"),url("/sites/all/themes/custom/cruk/fonts/museo/MuseoSans-500.ttf") format("truetype")}@font-face{font-family:"MuseoSans-700";font-display:swap;src:url("/sites/all/themes/custom/cruk/fonts/museo/MuseoSans-700.eot");src:url("/sites/all/themes/custom/cruk/fonts/museo/MuseoSans-700.eot?#iefix") format("embedded-opentype"),url("/sites/all/themes/custom/cruk/fonts/museo/MuseoSans-700.woff2") format("woff2"),url("/sites/all/themes/custom/cruk/fonts/museo/MuseoSans-700.woff") format("woff"),url("/sites/all/themes/custom/cruk/fonts/museo/MuseoSans-700.ttf") format("truetype")}@font-face{font-family:"Progress";font-display:swap;src:url("/sites/all/themes/custom/cruk/fonts/progress/Progress-Regular.woff")}@font-face{font-family:'CRUKIcons';src:url("/sites/all/themes/custom/cruk/fonts/cruk-icons/CRUKIcons.eot");src:url("/sites/all/themes/custom/cruk/fonts/cruk-icons/CRUKIcons.eot#iefix") format("embedded-opentype"),url("/sites/all/themes/custom/cruk/fonts/cruk-icons/CRUKIcons.woff") format("woff"),url("/sites/all/themes/custom/cruk/fonts/cruk-icons/CRUKIcons.ttf") format("truetype"),url("/sites/all/themes/custom/cruk/fonts/cruk-icons/CRUKIcons.svg#CRUKIcons") format("svg");font-weight:normal;font-style:normal}.cr-i{display:inline-block;font:normal normal normal 14px/1 CRUKIcons;font-size:inherit;text-rendering:auto;-webkit-font-smoothing:antialiased;-moz-osx-font-smoothing:grayscale;speak:none}.cr-i--chevron-down:before{content:"\e905"}body{font-family:"Arial",sans-serif;font-size:14px;padding:0}.container{max-width:960px}*,*:before,*:after{-moz-box-sizing:border-box;-webkit-box-sizing:border-box;box-sizing:border-box}.inner{width:auto;margin:0}@media screen and (min-width: 981px){.inner{width:940px;margin:0 auto}}@media screen and (max-width: 480px){.wrapper{overflow:visible}}@media screen and (min-width: 981px){.wrapper{overflow:hidden;padding-top:0}}/*! normalize.css v2.1.3 | MIT License | git.io/normalize */article,aside,details,figcaption,figure,footer,header,hgroup,main,nav,section,summary{display:block}audio,canvas,video{display:inline-block}audio:not([controls]){display:none;height:0}[hidden],template{display:none}html{font-family:sans-serif;-ms-text-size-adjust:100%;-webkit-text-size-adjust:100%}body{margin:0}a{background:transparent}a:focus{outline:thin dotted}a:active,a:hover{outline:0}h1{font-size:2em;margin:0.67em 0}abbr[title]{border-bottom:1px dotted}b,strong{font-weight:bold}dfn{font-style:italic}hr{-moz-box-sizing:content-box;box-sizing:content-box;height:0}mark{background:#ff0;color:#000}code,kbd,pre,samp{font-family:monospace, serif;font-size:1em}pre{white-space:pre-wrap}q{quotes:"\201C" "\201D" "\2018" "\2019"}small{font-size:80%}sub,sup{font-size:75%;line-height:0;position:relative;vertical-align:baseline}sup{top:-0.5em}sub{bottom:-0.25em}img{border:0}svg:not(:root){overflow:hidden}figure{margin:0}fieldset{border:1px solid #c0c0c0;margin:0 2px;padding:0.35em 0.625em 0.75em}legend{border:0;padding:0}button,input,select,textarea{font-family:inherit;font-size:100%;margin:0}button,input{line-height:normal}button,select{text-transform:none}button,html input[type="button"],input[type="reset"],input[type="submit"]{-webkit-appearance:button;cursor:pointer}button[disabled],html input[disabled]{cursor:default}input[type="checkbox"],input[type="radio"]{box-sizing:border-box;padding:0}input[type="search"]{-webkit-appearance:textfield;-moz-box-sizing:content-box;-webkit-box-sizing:content-box;box-sizing:content-box}input[type="search"]::-webkit-search-cancel-button,input[type="search"]::-webkit-search-decoration{-webkit-appearance:none}button::-moz-focus-inner,input::-moz-focus-inner{border:0;padding:0}textarea{overflow:auto;vertical-align:top}table{border-collapse:collapse;border-spacing:0}.container{width:auto;margin-left:auto;margin-right:auto}html{line-height:1.5}body{background-color:#f5f5f5;color:#333}h1{font-size:28px;line-height:1em}@media screen and (max-width: 640px){h1{font-size:23.996px;line-height:1.08em}}h2{font-size:21px;line-height:1.1em}main>h1{clear:both;margin-top:0;padding:15px 0 20px 10px}h1,h2{margin:0 0 .5em;color:#333}h2 a:link{text-decoration:none}p{margin:0 0 1em}header{overflow:hidden}input,button{white-space:normal}a:link{color:#2E008B}.more{margin-bottom:0;list-style:none}.more a{background:transparent url("/sites/all/themes/custom/cruk/images/pink-arrow.png") no-repeat 0 center;color:#e40085;text-decoration:none;padding-left:15px;font-weight:bold}input[type="submit"]{padding:11px 20px;font-family:"MuseoSansRounded-700","MuseoSans-700","Arial","Helvetica",sans-serif;font-size:16.002px;line-height:1.125em;text-align:center;color:#fff;background-color:#e40085;border:none;-moz-border-radius:3px;-webkit-border-radius:3px;border-radius:3px}.button{text-align:center;margin:.5em auto;display:inline-block}.secondary-button a {padding: 11px 10px;text-decoration: none !important;font-family: "MuseoSansRounded-700","MuseoSans-700","Arial","Helvetica",sans-serif;font-size: 16px;line-height: 21px;text-align: center;color: #e40085;background-color: #ffffff;border: 1px solid #e40085;border-radius: 3px}.button a{padding:11px 20px;text-decoration:none !important;display:block;font-family:"MuseoSansRounded-700","MuseoSans-700","Arial","Helvetica",sans-serif;font-size:16.002px;line-height:1.125em;text-align:center;color:#fff;background-color:#e40085;border:none;-moz-border-radius:3px;-webkit-border-radius:3px;border-radius:3px}.site-slogan{color:#2E008B}.lazyloader-icon{position:absolute;z-index:200}.lazyloader-icon{border:3px solid #E4E4E4;border-radius:50%;border-top:3px solid #00b6ed;width:20px;height:20px;-webkit-animation:spin 2s linear infinite;animation:spin 2s linear infinite;display:block;position:absolute;top:50%;left:50%;margin-left:-10px;margin-top:-10px}.siteinfo{background-color:#fff;display:flex;align-items:center;justify-content:space-between;padding-top:0}.siteinfo a{text-decoration:none}a.mhead-right{text-decoration:none}a.mhead-right:link,a.mhead-right:visited{padding:11px 20px;background-color:#e40085;-moz-border-radius:3px;-webkit-border-radius:3px;border-radius:3px;text-align:center;color:#fff;font-size:16.002px;line-height:1.125em;font-family:"MuseoSansRounded-700","MuseoSans-700","Arial","Helvetica",sans-serif}a.mhead-right:focus,a.mhead-right:hover,a.mhead-right:active{background-color:#F033A3}.site-slogan{font-size:1.7em;line-height:1.4em;font-family:"Progress","Arial","Helvetica",sans-serif;margin-bottom:0;color:#000}.site-slogan>a:hover,.site-slogan>a:visited{text-decoration:none;color:#2E008B}.page-node-64706 .siteinfo .mhead-right{display:none}#breadcrumb{background-color:#f5f5f5}#breadcrumb .breadcrumb{font-size:.833em;display:inline;color:#333}@media screen and (max-width: 480px){#breadcrumb{padding:9px 10px 0}}@media screen and (min-width: 481px) and (max-width: 640px){#breadcrumb{padding:9px 20px 0}}@media screen and (min-width: 641px) and (max-width: 800px){#breadcrumb{padding:9px 45px 0}}@media screen and (min-width: 801px) and (max-width: 980px){#breadcrumb{padding:11px 20px 0}}@media screen and (min-width: 981px){#breadcrumb{padding:13px 20px 0}}.in-maintenance .siteinfo{padding-bottom:10px}.in-maintenance #footer-txt{display:none}#dd-searchform{display:flex}#dd-searchform>input{box-sizing:border-box}#cruk-search{font-size:16px;padding:0 0 0 5px}#cruk-search .search{height:40px;width:145px;-moz-border-radius:4px;-webkit-border-radius:4px;border-radius:4px;border:2px solid #C8C8C8;border-right-width:0;border-top-right-radius:0;border-bottom-right-radius:0;padding:1px 0 0 1em}#cruk-search .search::placeholder{color:#C8C8C8}#cruk-search .searchsubmit{border:2px solid #C8C8C8;-moz-border-radius:4px;-webkit-border-radius:4px;border-radius:4px;border-bottom-left-radius:0;border-top-left-radius:0;border-left-width:0;background-color:#fff;color:#C8C8C8}#cruk-search .search:focus{border-color:#00B6ED;outline-width:0}#cruk-search .search:focus+.searchsubmit{border-color:#00B6ED;color:#2E008B}header{background-color:#fff}.header-region{border-top:1px solid #e3e3e3;border-bottom:1px solid #e3e3e3;background-color:#fafafa}.header-region nav{display:none}.megamenu{display:flex;justify-content:space-between;align-items:center;border:none;padding:0;margin:0;font-family:"MuseoSansRounded-500","MuseoSans-500","Arial","Helvetica",sans-serif;font-weight:500;list-style:none}.megamenu p{margin:0}.megamenu .clear-fix{float:none;clear:both;margin:0;padding:0;height:0;font-size:0;line-height:0}.megamenu>li>div{display:none}.mm-item>p{display:flex;height:60px}.mm-item-link:link,.mm-item-link:visited{color:#2E008B;font-family:"MuseoSansRounded-500","MuseoSans-500","Arial","Helvetica",sans-serif;font-weight:500;font-size:17px;text-decoration:none;padding:0 5px;line-height:20px;z-index:10;display:flex;align-items:center;border-left:1px solid transparent}.mm-item-link:link+.cr-i,.mm-item-link:visited+.cr-i{color:#A7A8AA;display:flex;align-items:center;border-right:1px solid transparent;padding-right:5px}.mm-item-link:last-child{border-right:1px solid transparent}.mm-item-link-hover:link,.mm-item-link-hover:visited{color:#e40085;padding-right:5px;border-color:#e3e3e3;z-index:1001}.mm-item-link-hover:link+.cr-i,.mm-item-link-hover:visited+.cr-i{color:#e40085;border-color:#e3e3e3}.mm-item.selected p>.mm-item-link.mm-item-link,.mm-item.selected p>.cr-i--chevron-down{color:#e40085}.mm-item-content{background-color:#fafafa;border:1px solid #e3e3e3;height:auto;margin-top:1px;position:absolute;z-index:101}.list-content,.list-content ul{padding:0;list-style:none}.toplevel{color:#2E008B;padding:12px 0 5px 20px;width:187px;float:left}.toplevel>p{font-size:14px;line-height:17px}.toplevel>p a{text-decoration:none;color:#2E008B}.toplevel>ul{height:auto;padding:10px 0 0}.toplevel li{margin-bottom:10px}.level3:link,.level3:visited{color:#333;text-decoration:none;font-size:14px;font-weight:normal;line-height:18px;padding-top:0}.level3:hover{color:#e40085}.cruk-logo img{width:100%;height:auto;display:block}#masthead_table{display:none !important}#mobile-rebrand-wrapper{display:block}@media screen and (min-width: 980px){#masthead_table{display:block !important}#mobile-rebrand-wrapper{margin:0 -16px;display:none}}.skip-link{width:100%}.skip-link .element-focusable:focus{position:absolute !important}#main-content:focus{outline:none !important}#mobile-navbar-container{background-color:#FAFAFA}#mobile-rebrand-wrapper #mobile-navbar-container>ul{margin-top:0;display:flex;justify-content:flex-start;height:50px;border-bottom:1px solid #e3e3e3}#mobile-rebrand-wrapper #mobile-navbar-container>ul li{display:flex;align-items:center}@media screen and (max-width: 800px){#top-page,#cruk-search,.site-slogan{display:none}.cruk-logo{padding-left:45px}.mhead-right{margin-right:45px}.siteinfo{padding-top:17px;padding-bottom:17px}}@media screen and (min-width: 481px) and (max-width: 800px){.site-slogan{display:none}}@media screen and (max-width: 480px){.cruk-logo{flex-basis:40%;padding-left:17px}.mhead-right{margin-right:15px}}@media screen and (min-width: 481px) and (max-width: 640px){.cruk-logo{padding-left:20px;width:140px}.mhead-right{margin-right:20px}}@media screen and (min-width: 800px) and (max-width: 980px){.cruk-logo{margin-left:20px}#cruk-nav{padding-left:20px}.mhead-right{margin-right:20px}#cruk-search{display:none}}@media screen and (min-width: 800px){.siteinfo{margin-top:30px;margin-bottom:17px}}.panel-related-row:before,.panel-related-row:after{content:" ";display:table}.panel-related-row:after{clear:both}.pane-promo,.feed-list,.pane-img-text,.pane-bundle-two-column-multi-alignment{background-color:#fff}.grey-panel{background-color:#e3e3e3}.blue-panel img,.white-panel img,.grey-panel img,.pane-show-hide img,.feed-list img,.pane-promo img,.pane-img-text img,.pane-bundle-two-column-multi-alignment img{width:100%;height:auto}.pane-bundle-donation-pane{display:none;background-repeat:no-repeat;background-size:cover;background-position:center}.pane-bundle-donation-pane.visible{display:block}.pane-bundle-donation-pane fieldset{padding:0;margin:0;border:0}.pane-bundle-donation-pane:after{display:none}.pane-bundle-donation-pane .pane-content{color:#fff;height:320px;margin-bottom:20px;text-align:center}.pane-bundle-donation-pane .pane-content:before{content:"";display:inline-block;height:100%;vertical-align:middle;margin-right:-0.25em}.pane-bundle-donation-pane .pane-content form{height:100%;display:block;padding:1em;position:relative}.pane-bundle-donation-pane .pane-content form>div{height:100%}.pane-bundle-donation-pane .pane-content h2{color:#fff;font-size:1.86em;line-height:1.1em;margin-bottom:.2em;margin-left:auto;margin-right:auto;max-width:260px}@media screen and (min-width: 800px){.pane-bundle-donation-pane .pane-content h2{line-height:1.4em;margin-bottom:.35em;max-width:600px}}.pane-bundle-donation-pane .pane-content .form-radios label{display:inline}.homepage .pane-bundle-donation-pane{background-repeat:no-repeat;border-radius:0;background-color:#2E008B}.homepage .pane-bundle-donation-pane .pane-content:before{display:none}.homepage .pane-bundle-donation-pane .pane-content form{height:100%;display:block;padding:1em;position:relative}@media screen and (min-width: 641px){.homepage .pane-bundle-donation-pane .pane-content form{float:right}}@media screen and (min-width: 801px){.homepage .pane-bundle-donation-pane .pane-content form{width:38%}}.homepage .pane-bundle-donation-pane .pane-content form>div{height:100%}.homepage .pane-bundle-donation-pane .pane-content form>div:before{content:"";display:inline-block;height:100%;vertical-align:middle;margin-right:-0.25em}.homepage .pane-bundle-donation-pane .form-steps{display:inline-block;vertical-align:bottom;margin-bottom:.5em}@media screen and (min-width: 641px){.homepage .pane-bundle-donation-pane .form-steps{vertical-align:middle}}.direct-donation-v2-pane.pane-bundle-donation-pane{display:block;background-position:30%}@media screen and (min-width: 800px){.direct-donation-v2-pane.pane-bundle-donation-pane{background-position:left}}@media screen and (min-width: 640px){.direct-donation-v2-pane.pane-bundle-donation-pane{background-position:15%}}.direct_donation_v2#cruk-donate-donation-pane-form .branding-content{height:100%;width:100%;padding:1em;display:table}@media screen and (min-width: 640px){.direct_donation_v2#cruk-donate-donation-pane-form .branding-content{padding-bottom:1em;width:63%}}.direct_donation_v2#cruk-donate-donation-pane-form .branding-content .branding-content-inner{display:table-cell;padding-bottom:0;vertical-align:bottom}@media screen and (min-width: 640px){.direct_donation_v2#cruk-donate-donation-pane-form .branding-content .branding-content-inner{padding:0 25% 0 0}}.direct_donation_v2#cruk-donate-donation-pane-form .donate-panel-heading{font-size:22px;line-height:normal;text-shadow:0 0 20px rgba(0,0,0,0.75);width:100%;padding:0 0 .5em;margin-bottom:0;max-width:100%;text-align:center;letter-spacing:.03em}@media screen and (min-width: 640px){.direct_donation_v2#cruk-donate-donation-pane-form .donate-panel-heading{font-size:26px;line-height:28px;text-align:left;padding:0 0 7% 5%}}.direct_donation_v2#cruk-donate-donation-pane-form .donate-panel-subheading{display:none}.direct_donation_v2#cruk-donate-donation-pane-form .direct-donation-v2-form{background-color:#fff;border-radius:0;z-index:1;display:block;margin-bottom:20px;padding:2em;position:relative;float:left;width:100%;box-sizing:border-box}@media screen and (min-width: 640px){.direct_donation_v2#cruk-donate-donation-pane-form .direct-donation-v2-form{float:none;padding:1em;position:absolute;top:3em;right:6em;max-width:calc(28% - 2em);margin-bottom:0}}@media screen and (max-width: 800px) and (min-width: 640px){.direct_donation_v2#cruk-donate-donation-pane-form .direct-donation-v2-form{top:2em;right:2em;max-width:calc(33% - 2em)}}@media screen and (min-width: 640px){.homepage .direct_donation_v2#cruk-donate-donation-pane-form .branding-content{padding-bottom:1em;width:67%}}.homepage .direct_donation_v2#cruk-donate-donation-pane-form .donate-panel-heading{padding:0 0 .5em;margin-bottom:0}@media screen and (min-width: 640px){.homepage .direct_donation_v2#cruk-donate-donation-pane-form .donate-panel-heading{font-size:26px;line-height:40px;text-align:left;padding:0 0 0 20%}}.homepage .direct_donation_v2#cruk-donate-donation-pane-form .donate-panel-subheading{display:block;font-size:16px}@media screen and (min-width: 640px){.homepage .direct_donation_v2#cruk-donate-donation-pane-form .donate-panel-subheading{font-size:18px;text-align:left;margin-left:20%}}.homepage .direct_donation_v2#cruk-donate-donation-pane-form .direct-donation-v2-form{margin-bottom:0}@media screen and (min-width: 640px){.homepage .direct_donation_v2#cruk-donate-donation-pane-form .direct-donation-v2-form{right:2em;top:2em}}@media screen and (max-width: 640px){.direct-donation-v2-pane.pane-bundle-donation-pane .pane-content:before{display:none}}.direct_donation_v2#cruk-donate-donation-pane-form{padding:0;width:100%;font-family:"MuseoSansRounded-500","MuseoSans-500","Arial","Helvetica",sans-serif;display:block}@media screen and (min-width: 640px){.direct_donation_v2#cruk-donate-donation-pane-form{float:right}}.direct_donation_v2#cruk-donate-donation-pane-form>div:before{display:none}.direct_donation_v2#cruk-donate-donation-pane-form #edit-donation-type input[name="donation_type"]{position:fixed;opacity:0}.direct_donation_v2#cruk-donate-donation-pane-form #edit-donation-type div{width:47%;display:inline-block;font-size:20px}@media screen and (min-width: 640px){.direct_donation_v2#cruk-donate-donation-pane-form #edit-donation-type div{font-size:14px}}.direct_donation_v2#cruk-donate-donation-pane-form #edit-donation-type label{background-color:#fff;border:1px solid #2E008B;color:#2E008B;display:block;font-weight:normal;padding:12px}@media screen and (min-width: 640px){.direct_donation_v2#cruk-donate-donation-pane-form #edit-donation-type label{padding:8px}}.direct_donation_v2#cruk-donate-donation-pane-form #edit-donation-type label:hover,.direct_donation_v2#cruk-donate-donation-pane-form #edit-donation-type label:focus{background-color:#2E008B !important;color:#fff;cursor:pointer}.direct_donation_v2#cruk-donate-donation-pane-form #edit-donation-type input[name="donation_type"]:checked+label{color:#fff;background-color:#2E008B}.direct_donation_v2#cruk-donate-donation-pane-form #edit-donation-type{display:flex;justify-content:space-between}.direct_donation_v2#cruk-donate-donation-pane-form #edit-monthly div,.direct_donation_v2#cruk-donate-donation-pane-form #edit-single div{display:flex;font-family:"MuseoSansRounded-500","MuseoSans-500","Arial","Helvetica",sans-serif;width:100%;color:#2E008B;background-color:#fff;margin-right:5%}.direct_donation_v2#cruk-donate-donation-pane-form #edit-monthly div div:last-child,.direct_donation_v2#cruk-donate-donation-pane-form #edit-single div div:last-child{margin-right:0px}.direct_donation_v2#cruk-donate-donation-pane-form #edit-monthly div input,.direct_donation_v2#cruk-donate-donation-pane-form #edit-single div input{position:fixed;opacity:0}.direct_donation_v2#cruk-donate-donation-pane-form #edit-monthly div div,.direct_donation_v2#cruk-donate-donation-pane-form #edit-single div div{width:47%;display:inline-block;font-size:20px}@media screen and (min-width: 640px){.direct_donation_v2#cruk-donate-donation-pane-form #edit-monthly div div,.direct_donation_v2#cruk-donate-donation-pane-form #edit-single div div{font-size:14px}}@media screen and (max-width: 638px){.direct_donation_v2#cruk-donate-donation-pane-form #edit-monthly div div,.direct_donation_v2#cruk-donate-donation-pane-form #edit-single div div{padding-top:30px;display:inline-block}}.direct_donation_v2#cruk-donate-donation-pane-form #edit-monthly div label,.direct_donation_v2#cruk-donate-donation-pane-form #edit-single div label{background-color:#fff;border:2px solid #e3e3e3;color:#2E008B;display:block;font-weight:normal;padding:12px}@media screen and (min-width: 640px){.direct_donation_v2#cruk-donate-donation-pane-form #edit-monthly div label,.direct_donation_v2#cruk-donate-donation-pane-form #edit-single div label{padding:4px 0px 4px 0px}}.direct_donation_v2#cruk-donate-donation-pane-form #edit-monthly div label:hover,.direct_donation_v2#cruk-donate-donation-pane-form #edit-monthly div label:focus,.direct_donation_v2#cruk-donate-donation-pane-form #edit-single div label:hover,.direct_donation_v2#cruk-donate-donation-pane-form #edit-single div label:focus{background-color:#2E008B !important;color:#fff;cursor:pointer}.direct_donation_v2#cruk-donate-donation-pane-form #edit-monthly div input:checked+label,.direct_donation_v2#cruk-donate-donation-pane-form #edit-single div input:checked+label{color:#fff;background-color:#2E008B}@media screen and (min-width: 640px){.direct_donation_v2#cruk-donate-donation-pane-form #edit-monthly div,.direct_donation_v2#cruk-donate-donation-pane-form #edit-single div{padding:9px 0;font-size:inherit}}.direct_donation_v2#cruk-donate-donation-pane-form #edit-single>div,.direct_donation_v2#cruk-donate-donation-pane-form #edit-monthly>div{border:none}@media screen and (min-width: 640px){.direct_donation_v2#cruk-donate-donation-pane-form #edit-single>div,.direct_donation_v2#cruk-donate-donation-pane-form #edit-monthly>div{padding:9px 0;font-size:inherit}}.direct_donation_v2#cruk-donate-donation-pane-form .amount-separator{font-family:"MuseoSansRounded-500","MuseoSans-500","Arial","Helvetica",sans-serif;font-size:20px;margin-bottom:5%;color:#2E008B}@media screen and (min-width: 640px){.direct_donation_v2#cruk-donate-donation-pane-form .amount-separator{font-size:16px}}@media screen and (max-width: 638px){.direct_donation_v2#cruk-donate-donation-pane-form .amount-separator{padding-top:15px}}.direct_donation_v2#cruk-donate-donation-pane-form .pound-symbol{position:absolute;font-size:20px;margin:13px 0 0 12px;color:#2E008B;font-family:"MuseoSansRounded-500","MuseoSans-500","Arial","Helvetica",sans-serif}@media screen and (min-width: 640px){.direct_donation_v2#cruk-donate-donation-pane-form .pound-symbol{font-size:18px;margin:8px 0 0 12px}}.direct_donation_v2#cruk-donate-donation-pane-form #edit-amount-other{width:100%;padding:14px 10px 14px 35px;font-size:20px;color:#2E008B;font-family:"MuseoSansRounded-500","MuseoSans-500","Arial","Helvetica",sans-serif;border:2px solid #e3e3e3}@media screen and (min-width: 640px){.direct_donation_v2#cruk-donate-donation-pane-form #edit-amount-other{padding:10px 10px 10px 35px;font-size:15px}}.direct_donation_v2#cruk-donate-donation-pane-form #edit-amount-other:focus{border-color:#e40085;outline:0}.direct_donation_v2#cruk-donate-donation-pane-form #edit-amount-other::placeholder{font-size:20px;color:#C8C9C7;font-family:"MuseoSansRounded-500","MuseoSans-500","Arial","Helvetica",sans-serif}@media screen and (min-width: 640px){.direct_donation_v2#cruk-donate-donation-pane-form #edit-amount-other::placeholder{font-size:15px}}.direct_donation_v2#cruk-donate-donation-pane-form .input-other-amnt-wrapper{float:none;display:block;position:relative}.direct_donation_v2#cruk-donate-donation-pane-form .submit-btn{width:100%;height:50px;font-family:"MuseoSansRounded-500","MuseoSans-500","Arial","Helvetica",sans-serif;font-size:20px;color:#fff;background:#e40085;margin:10% 0 0 0;padding:0}.direct_donation_v2#cruk-donate-donation-pane-form .submit-btn:hover{background:#F033A3}@media screen and (min-width: 640px){.direct_donation_v2#cruk-donate-donation-pane-form .submit-btn{font-size:16px;height:42px}}fieldset{-moz-border-radius:3px;-webkit-border-radius:3px;border-radius:3px;border:1px solid #e3e3e3;background-color:#fff;margin:0 0 20px 0;padding:15px 20px 20px;clear:both}
/*# sourceMappingURL=critical.css.map */
</style>
<style>
@import url("https://www.cancerresearchuk.org/sites/all/modules/contrib/jquery_update/replace/ui/themes/base/minified/jquery.ui.core.min.css?");
@import url("https://www.cancerresearchuk.org/sites/all/modules/contrib/jquery_update/replace/ui/themes/base/minified/jquery.ui.theme.min.css?");
</style>
<style>
@import url("https://www.cancerresearchuk.org/modules/aggregator/aggregator.css?");
@import url("https://www.cancerresearchuk.org/sites/all/modules/custom/cruk_gc_timeline/css/grand_challenge_timeline.css?");
@import url("https://www.cancerresearchuk.org/modules/field/theme/field.css?");
@import url("https://www.cancerresearchuk.org/sites/all/modules/contrib/geofield_gmap/geofield_gmap.css?");
@import url("https://www.cancerresearchuk.org/modules/node/node.css?");
@import url("https://www.cancerresearchuk.org/modules/search/search.css?");
@import url("https://www.cancerresearchuk.org/modules/user/user.css?");
@import url("https://www.cancerresearchuk.org/sites/all/modules/contrib/extlink/css/extlink.css?");
@import url("https://www.cancerresearchuk.org/sites/all/modules/contrib/views/css/views.css?");
@import url("https://www.cancerresearchuk.org/sites/all/modules/contrib/ckeditor/css/ckeditor.css?");
</style>
<style>
@import url("https://www.cancerresearchuk.org/sites/all/modules/contrib/ctools/css/ctools.css?");
@import url("https://www.cancerresearchuk.org/sites/all/modules/contrib/panels/css/panels.css?");
@import url("https://www.cancerresearchuk.org/sites/all/themes/custom/cruk_grand_challenge/layouts/grand_challenge_winners/grand_challenge_winners.css?");
@import url("https://www.cancerresearchuk.org/sites/all/modules/custom/cruk_donate/selectmenu/jquery.ui.selectmenu.css?");
@import url("https://www.cancerresearchuk.org/sites/all/modules/contrib/node_embed/plugins/node_embed/node_embed.css?");
</style>
<style>
@import url("https://www.cancerresearchuk.org/sites/all/themes/custom/cruk/css/tabs_to_accordion.css?");
@import url("https://www.cancerresearchuk.org/sites/all/themes/custom/cruk/css/style.css?");
@import url("https://www.cancerresearchuk.org/sites/all/themes/custom/cruk/css/cruk.menus.css?");
@import url("https://www.cancerresearchuk.org/sites/all/themes/custom/cruk/css/mobile.menu.css?");
@import url("https://www.cancerresearchuk.org/sites/all/themes/custom/cruk/css/slick.css?");
</style>
<style media="print">
@import url("https://www.cancerresearchuk.org/sites/all/themes/custom/cruk/css/print.css?");
</style>
<style>
@import url("https://www.cancerresearchuk.org/sites/default/files/css_injector/css_injector_31.css?");
@import url("https://www.cancerresearchuk.org/sites/default/files/css_injector/css_injector_131.css?");
@import url("https://www.cancerresearchuk.org/sites/default/files/css_injector/css_injector_156.css?");
@import url("https://www.cancerresearchuk.org/sites/default/files/css_injector/css_injector_196.css?");
@import url("https://www.cancerresearchuk.org/sites/default/files/css_injector/css_injector_201.css?");
@import url("https://www.cancerresearchuk.org/sites/default/files/css_injector/css_injector_206.css?");
@import url("https://www.cancerresearchuk.org/sites/default/files/css_injector/css_injector_211.css?");
@import url("https://www.cancerresearchuk.org/sites/default/files/css_injector/css_injector_226.css?");
@import url("https://www.cancerresearchuk.org/sites/default/files/css_injector/css_injector_241.css?");
</style>
<link rel="stylesheet" href="https://www.cancerresearchuk.org/sites/default/files/css_injector/css_injector_251.css?" media="screen">
<style>
@import url("https://www.cancerresearchuk.org/sites/default/files/css_injector/css_injector_261.css?");
@import url("https://www.cancerresearchuk.org/sites/default/files/css_injector/css_injector_276.css?");
@import url("https://www.cancerresearchuk.org/sites/default/files/css_injector/css_injector_281.css?");
@import url("https://www.cancerresearchuk.org/sites/default/files/css_injector/css_injector_291.css?");
@import url("https://www.cancerresearchuk.org/sites/default/files/css_injector/css_injector_296.css?");
@import url("https://www.cancerresearchuk.org/sites/default/files/css_injector/css_injector_306.css?");
@import url("https://www.cancerresearchuk.org/sites/default/files/css_injector/css_injector_361.css?");
@import url("https://www.cancerresearchuk.org/sites/default/files/css_injector/css_injector_371.css?");
@import url("https://www.cancerresearchuk.org/sites/default/files/css_injector/css_injector_376.css?");
@import url("https://www.cancerresearchuk.org/sites/default/files/css_injector/css_injector_426.css?");
@import url("https://www.cancerresearchuk.org/sites/default/files/css_injector/css_injector_441.css?");
@import url("https://www.cancerresearchuk.org/sites/default/files/css_injector/css_injector_466.css?");
@import url("https://www.cancerresearchuk.org/sites/default/files/css_injector/css_injector_471.css?");
</style>
<style media="screen">
@import url("https://www.cancerresearchuk.org/sites/default/files/css_injector/css_injector_516.css?");
</style>
<link rel="stylesheet" href="https://www.cancerresearchuk.org/sites/default/files/css_injector/css_injector_561.css?">
<style>
@import url("https://www.cancerresearchuk.org/sites/default/files/css_injector/css_injector_576.css?");
</style>
<link rel="stylesheet" href="https://www.cancerresearchuk.org/sites/default/files/css_injector/css_injector_581.css?">
<style>
@import url("https://www.cancerresearchuk.org/sites/default/files/css_injector/css_injector_601.css?");
</style>
<link rel="stylesheet" href="https://www.cancerresearchuk.org/sites/default/files/css_injector/css_injector_610.css?">
<style>
@import url("https://www.cancerresearchuk.org/sites/default/files/css_injector/css_injector_616.css?");
@import url("https://www.cancerresearchuk.org/sites/default/files/css_injector/css_injector_617.css?");
</style>
<link rel="stylesheet" href="https://www.cancerresearchuk.org/sites/default/files/css_injector/css_injector_619.css?">
<style>
@import url("https://www.cancerresearchuk.org/sites/default/files/css_injector/css_injector_620.css?");
</style>
  <script>
    window.CancerResearchUK = {};
  </script>
    <!--[if lt IE 9]>
  <script src="https://www.cancerresearchuk.org/sites/all/themes/contrib/mothership/mothership/js/respond.min.js"></script>
  <script src="https://www.cancerresearchuk.org/sites/all/themes/contrib/mothership/mothership/js/html5.js"></script>
  <![endif]-->

  </head>

<body class="not-front no-sidebars page-node page-node- page-node-190976 node-type-landing-page">

<!-- The gtm id code variable ($gtm_code) is set in gtm-header.inc.php -->

  <!-- Google Tag Manager (noscript) -->
  <noscript><iframe src="https://www.googletagmanager.com/ns.html?id=GTM-W3ZV" height="0" width="0" style="display:none;visibility:hidden"></iframe></noscript>
  <!-- End Google Tag Manager (noscript) -->

<div id="top-page">
  <div class="inner">
    <div class="skip-link"><a href="#main-content" class="element-invisible element-focusable">Skip to main content</a></div>
  </div>
</div>


<header role="banner">
  <div class="siteinfo inner">
          <div class="cruk-logo">
        <a href="/" title="Cancer Research UK Homepage" rel="home">
          <img src="https://www.cancerresearchuk.org/sites/all/themes/custom/cruk_integrated_campaign/logo.svg" width="222" height="86" alt="Cancer Research UK Homepage">
        </a>
      </div>
    
          <p class="site-slogan">Together we are beating cancer</p>
    
    
    <div id="cruk-search">
      <form action="https://find.cancerresearchuk.org/" id="dd-searchform">
        <input type="hidden" value="1" name="siteid">
        <input type="text" class="search" placeholder="Search" name="q" id="q">
        <button aria-label="Search" name="searchsubmit" id="searchsubmit" class="searchsubmit">
          <span class="cr-i cr-i--search"></span>
        </button>
      </form>
    </div>



    <a class="mhead-right" href="/get-involved/donate/">Donate</a>
  </div><!-- #siteinfo -->

  <div class="header-region">
    <div class="inner">
            <!-- start: ul megamenu -->
      <div>
    <div id="cruk-nav">
      <div id="masthead_table">
        <ul class="megamenu" id="drupal-mdd"><li class="mm-item"><p><a href="/about-cancer/" class="mm-item-link">About cancer</a><span class="cr-i cr-i--chevron-down"></span></p>
      <div style="width: 940px">
          <ul class="list-content" id="about-cancer-menu"><li class="toplevel"><p><a href="/about-cancer/type" class="level2">Cancer types</a></p><ul><li><a href="/about-cancer/breast-cancer" class="level3">Breast cancer</a></li><li><a href="/about-cancer/bowel-cancer" class="level3">Bowel cancer</a></li><li><a href="/about-cancer/lung-cancer" class="level3">Lung cancer</a></li><li><a href="/about-cancer/prostate-cancer" class="level3">Prostate cancer</a></li></ul></li><li class="toplevel"><p><a href="/about-cancer/cancer-in-general" class="level2">Cancers in general</a></p><ul><li><a href="/about-cancer/cancer-symptoms" class="level3">Symptoms</a></li><li><a href="/about-cancer/screening" class="level3">Screening</a></li><li><a href="/about-cancer/tests-and-scans" class="level3">Tests</a></li><li><a href="/about-cancer/treatment" class="level3">Treatment</a></li><li><a href="/about-cancer/find-a-clinical-trial" class="level3">Clinical trials</a></li></ul></li><li class="toplevel"><p><a href="/about-cancer/causes-of-cancer" class="level2">Causes of cancer</a></p><ul><li><a href="/about-cancer/causes-of-cancer/smoking-and-cancer" class="level3">Smoking</a></li><li><a href="/about-cancer/causes-of-cancer/alcohol-and-cancer" class="level3">Alcohol</a></li><li><a href="/about-cancer/causes-of-cancer/diet-and-cancer" class="level3">Diet</a></li><li><a href="/about-cancer/causes-of-cancer/bodyweight-and-cancer" class="level3">Obesity</a></li><li><a href="/about-cancer/causes-of-cancer/sun-uv-and-cancer" class="level3">Sun and UV</a></li></ul></li><li class="toplevel"><p><a href="/about-cancer/coping-with-cancer" class="level2">Coping with cancer</a></p><ul><li><a href="/about-cancer/coping-with-cancer/coping-physically/" class="level3">Managing symptoms and side effects</a></li><li><a href="/about-cancer/coping/mental-health-cancer" class="level3">Mental health and cancer</a></li><li><a href="/about-cancer/coping-with-cancer/coping-practically/" class="level3">Money and travel</a></li><li><a href="/about-cancer/coping-with-cancer/dying/" class="level3">Death and dying</a></li><li><a href="https://cancerchat.cancerresearchuk.org/" class="level3">Cancer Chat forum</a></li></ul></li><li class="toplevel"><p><a href="/health-professional" class="level2">Health Professionals</a></p><ul><li><a href="/health-professional/cancer-statistics" class="level3">Cancer Statistics</a></li><li><a href="/health-professional/screening" class="level3">Cancer Screening</a></li><li><a href="/health-professional/learning-and-support" class="level3">Learning and Support</a></li><li><a href="/health-professional/learning-and-development-tools/nice-cancer-referral-guidelines" class="level3">NICE suspected cancer referral guidelines</a></li></ul></li></ul>
      </div>
    </li><li class="mm-item"><p><a href="/get-involved" class="mm-item-link">Get involved</a><span class="cr-i cr-i--chevron-down"></span></p>
      <div style="width: 940px">
          <ul class="list-content" id="get-involved-menu"><li class="toplevel"><p><a href="/get-involved/donate" class="level2">Donate</a></p><ul><li><a href="/get-involved/donate" class="level3">Make a donation</a></li><li><a href="/get-involved/leave-a-legacy-gift-in-your-will" class="level3">Leave a legacy gift</a></li><li><a href="/get-involved/donate/donate-in-memory" class="level3">Donate in memory</a></li><li><a href="/get-involved/donate/philanthropy" class="level3">Philanthropy</a></li><li><a href="/node/143661" class="level3">Weekly Lottery</a></li></ul></li><li class="toplevel"><p><a href="/get-involved/find-an-event" class="level2">Find an event</a></p><ul><li><a href="https://raceforlife.cancerresearchuk.org/" class="level3">Race for Life</a></li><li><a href="/get-involved/find-an-event/charity-runs" class="level3">Charity runs</a></li><li><a href="/get-involved/find-an-event/charity-walks-treks-and-hikes" class="level3">Charity walks</a></li><li><a href="https://find.cancerresearchuk.org/events?size=n_20_n&amp;sort-field=startDate&amp;sort-direction=asc" class="level3">Search events</a></li><li><a href="http://relay.cancerresearchuk.org" class="level3">Relay For Life</a></li></ul></li><li class="toplevel"><p><a href="/get-involved/volunteer" class="level2">Volunteer</a></p><ul><li><a href="/get-involved/volunteer/volunteer-in-our-shops" class="level3">Volunteer in our shops</a></li><li><a href="/get-involved/volunteer/help-at-an-event" class="level3">Help at an event</a></li><li><a href="/get-involved/volunteer/help-us-raise-money" class="level3">Help us raise money</a></li><li><a href="/how-to-cancer-campaign" class="level3">Campaign for us</a></li></ul></li><li class="toplevel"><p><a href="/get-involved/do-your-own-fundraising" class="level2">Do your own fundraising</a></p><ul><li><a href="/get-involved/do-your-own-fundraising/fundraising-ideas" class="level3">Fundraising ideas</a></li><li><a href="/get-involved/do-your-own-fundraising/get-fundraising-pack" class="level3">Get a fundraising pack</a></li><li><a href="/get-involved/do-your-own-fundraising/return-your-money" class="level3">Return fundraising money</a></li><li><a href="/get-involved/do-your-own-fundraising/target-your-fundraising" class="level3">Fundraise by cancer type</a></li><li><a href="/get-involved/do-your-own-fundraising/practical-fundraising-help/set-up-a-cancer-research-uk-giving-page" class="level3">Set up a Cancer Research UK Giving Page</a></li></ul></li><li class="toplevel"><p>More...</p><ul><li><a href="/get-involved/find-a-shop" class="level3">Find a shop or superstore</a></li><li><a href="/get-involved/become-a-partner" class="level3">Become a partner</a></li><li><a href="/get-involved/donate/kids-and-teens" class="level3">Cancer Research UK for Children &amp; Young People</a></li><li><a href="/get-involved/we-are" class="level3">Our We Are campaign</a></li></ul></li></ul>
      </div>
    </li><li class="mm-item"><p><a href="/our-research" class="mm-item-link">Our research</a><span class="cr-i cr-i--chevron-down"></span></p>
      <div style="width: 940px">
          <ul class="list-content" id="our-research-menu"><li class="toplevel"><p><a href="/our-research/our-research-by-cancer-type" class="level2">By cancer type</a></p><ul><li><a href="/node/198836" class="level3">Brain tumours</a></li><li><a href="/node/199166" class="level3">Skin cancer</a></li><li><a href="/node/196346/" class="level3">Breast cancer</a></li><li><a href="/our-research/our-research-by-cancer-type" class="level3">All cancer types</a></li></ul></li><li class="toplevel"><p><a href="/our-progress" class="level2">Our achievements timeline</a></p><ul></ul></li><li class="toplevel"><p><a href="/our-research/our-research-by-cancer-subject" class="level2">By cancer topic</a></p><ul><li><a href="/node/206811" class="level3">New treatments</a></li><li><a href="/our-research/our-research-by-cancer-subject/our-research-on-cancer-biology" class="level3">Cancer biology</a></li><li><a href="/node/206651" class="level3">Cancer drugs</a></li><li><a href="/our-research/our-research-by-cancer-subject" class="level3">All cancer subjects</a></li></ul></li><li class="toplevel"><p><a href="/funding-for-researchers/our-research-strategy" class="level2">Our research strategy</a></p><ul></ul></li><li class="toplevel"><p><a href="/our-research/involving-animals-in-research" class="level2">Involving animals in research</a></p><ul></ul></li></ul>
      </div>
    </li><li class="mm-item selected"><p><a href="/funding-for-researchers" class="mm-item-link">Funding for researchers</a><span class="cr-i cr-i--chevron-down"></span></p>
      <div style="width: 940px">
          <ul class="list-content" id="funding-for-researchers-menu"><li class="toplevel"><p><a href="/funding-for-researchers" class="level2">Research opportunities</a></p><ul><li><a href="/funding-for-researchers/research-opportunities-in-basic-science-and-discovery-research" class="level3">For discovery researchers</a></li><li><a href="/funding-for-researchers/clinical-research" class="level3">For clinical researchers</a></li><li><a href="/funding-for-researchers/research-opportunities-in-population-and-behavioural-research" class="level3">For population researchers</a></li><li><a href="/funding-for-researchers/drug-discovery-and-development" class="level3">In drug discovery &amp; development</a></li><li><a href="/funding-for-researchers/research-opportunities-in-early-detection-and-diagnosis" class="level3">In early detection &amp; diagnosis</a></li><li><a href="/funding-for-researchers/develop-your-research-career" class="level3">Develop your research career</a></li></ul></li><li class="toplevel"><p><a href="/funding-for-researchers/our-funding-schemes?items_per_page=40" class="level2">Our funding schemes</a></p><ul><li><a href="/funding-for-researchers/our-funding-schemes/career-development-fellowship" class="level3">Career Development Fellowship</a></li><li><a href="/funding-for-researchers/our-funding-schemes/discovery-programme-awards" class="level3">Discovery Programme Awards</a></li><li><a href="/funding-for-researchers/our-funding-schemes/clinical-research-funding-scheme" class="level3">Clinical Research Funding Scheme</a></li><li><a href="/funding-for-researchers/our-funding-schemes/biology-to-prevention-award" class="level3">Biology to Prevention Award</a></li><li><a href="/funding-for-researchers/our-funding-schemes" class="level3">View all schemes and deadlines</a></li></ul></li><li class="toplevel"><p><a href="/funding-for-researchers/applying-for-funding" class="level2">Applying for funding</a></p><ul><li><a href="/funding-for-researchers/applying-for-funding/start-your-funding-application-online" class="level3">Start your application online</a></li><li><a href="/funding-for-researchers/applying-for-funding/how-to-make-a-successful-application" class="level3">How to make a successful application</a></li><li><a href="/funding-for-researchers/applying-for-funding/funding-committees" class="level3">Funding committees</a></li><li><a href="/funding-for-researchers/applying-for-funding/how-to-make-a-successful-application/successful-applicant-case-studies" class="level3">Successful applicant case studies</a></li></ul></li><li class="toplevel"><p><a href="/funding-for-researchers/how-we-deliver-research" class="level2">How we deliver research</a></p><ul><li><a href="/funding-for-researchers/our-research-strategy" class="level3">Our research strategy</a></li><li><a href="/funding-for-researchers/our-research-infrastructure" class="level3">Our research infrastructure</a></li><li><a href="/funding-for-researchers/research-events-and-conferences" class="level3">Events and conferences</a></li><li><a href="/funding-for-researchers/how-we-deliver-research/our-research-partnerships" class="level3">Our research partnerships</a></li><li><a href="/funding-for-researchers/facts-and-figures-about-our-research-funding" class="level3">Facts &amp; figures about our funding</a></li></ul></li><li class="toplevel"><p>More...</p><ul><li><a href="/funding-for-researchers/patient-involvement-toolkit-for-researchers" class="level3">Patient involvement toolkit for researchers</a></li><li><a href="/funding-for-researchers/how-we-deliver-research/recently-funded-awards" class="level3">Recently funded awards</a></li><li><a href="/funding-for-researchers/manage-your-research-grant" class="level3">Manage your research grant</a></li><li><a href="/home/funding-for-researchers/manage-your-research-grant/tell-us-about-new-publications" class="level3">Notify us of new publications</a></li></ul></li></ul>
      </div>
    </li><li class="mm-item"><p><a href="/get-involved/ways-to-shop" class="mm-item-link">Shop</a><span class="cr-i cr-i--chevron-down"></span></p>
      <div style="width: 940px">
          <ul class="list-content" id="shop-menu"><li class="toplevel"><p><a href="/get-involved/find-a-shop" class="level2">Find a shop</a></p><ul><li><a href="/get-involved/volunteer/volunteer-in-our-shops" class="level3">Volunteer in a shop</a></li><li><a href="/get-involved/donate/donate-goods" class="level3">Donate goods to a shop</a></li><li><a href="/get-involved/ways-to-shop/superstores" class="level3">Our superstores</a></li></ul></li><li class="toplevel"><p><a href="https://shop.cancerresearchuk.org/" class="level2">Shop online</a></p><ul><li><a href="https://shop.cancerresearchuk.org/pages/race-for-life" class="level3">Race for Life</a></li><li><a href="https://shop.cancerresearchuk.org/products/wedding-favours" class="level3">Wedding favours</a></li><li><a href="https://shop.cancerresearchuk.org/cancer-care" class="level3">Cancer Care</a></li><li><a href="https://flowershop.cancerresearchuk.org/" class="level3">Flower Shop</a></li></ul></li><li class="toplevel"><p><a href="https://www.ebay.co.uk/str/ukcancerresearch" class="level2">Our eBay store</a></p><ul><li><a href="https://www.ebay.co.uk/str/ukcancerresearch/Dresses/_i.html?_storecat=13763243016" class="level3">Dresses</a></li><li><a href="https://www.ebay.co.uk/str/ukcancerresearch/Shoes-and-Boots/_i.html?_storecat=13763242016" class="level3">Shoes and boots</a></li><li><a href="https://www.ebay.co.uk/str/ukcancerresearch/Bags-Purses/_i.html?_storecat=13869673016" class="level3">Bags and purses</a></li></ul></li></ul>
      </div>
    </li><li class="mm-item"><p><a href="/about-us/" class="mm-item-link">About us</a><span class="cr-i cr-i--chevron-down"></span></p>
      <div style="width: 940px">
          <ul class="list-content" id="about-us-menu"><li class="toplevel"><p><a href="/about-us" class="level2">What we do</a></p><ul><li><a href="/our-research" class="level3">We beat cancer</a></li><li><a href="/get-involved/how-your-support-helps" class="level3">We fundraise</a></li><li><a href="/about-us/we-develop-policy" class="level3">We develop policy</a></li><li><a href="/global-role" class="level3">Our global role</a></li></ul></li><li class="toplevel"><p><a href="/about-us/our-organisation" class="level2">Our organisation</a></p><ul><li><a href="/about-us/our-organisation/beating-cancer-sooner-our-strategy" class="level3">Our strategy</a></li><li><a href="/about-us/how-we-are-run/our-trustees" class="level3">Our Trustees</a></li><li><a href="/about-us/how-we-are-run/chief-executive-and-executive-board" class="level3">CEO and Executive Board</a></li><li><a href="/about-us/our-organisation/how-we-spend-your-money" class="level3">How we spend your money</a></li></ul></li><li class="toplevel"><p><a href="/about-us/careers" class="level2">Careers</a></p><ul><li><a href="/about-us/careers/early-in-career-opportunities" class="level3">Early careers</a></li><li><a href="/about-us/careers/teams" class="level3">Our teams</a></li><li><a href="/about-us/careers/benefits" class="level3">Benefits</a></li></ul></li><li class="toplevel"><p><a href="https://news.cancerresearchuk.org/" class="level2">Cancer news</a></p><ul><li><a href="https://news.cancerresearchuk.org/" class="level3">Cancer News</a></li><li><a href="https://news.cancerresearchuk.org/for-researchers/" class="level3">For Researchers</a></li><li><a href="https://news.cancerresearchuk.org/for-supporters/" class="level3">For Supporters</a></li></ul></li><li class="toplevel"><p>More...</p><ul><li><a href="/about-us/contact-us" class="level3">Contact us</a></li><li><a href="/about-us/press-office" class="level3">Press office</a></li><li><a href="https://publications.cancerresearchuk.org" class="level3">Publications</a></li><li><a href="/about-us/contact-us/opt-in-form" class="level3">Update your contact preferences</a></li></ul></li></ul>
      </div>
    </li></ul>
      </div>
    </div>
  </div>
      <noscript>
        <ul class="megamenu js-off">
          <!-- start: top li -->
          <li class="mm-item"><p><a class="mm-item-link" href="/about-cancer">ABOUT CANCER</a></p></li>
          <!-- end: top li -->
          <!-- ignore empty title -->
          <!-- ignore empty title -->
          <!-- ignore empty title -->
          <!-- ignore empty title -->
          <!-- start: top li -->
          <li class="mm-item"><p><a class="mm-item-link" href="/get-involved">GET INVOLVED</a></p></li>
          <!-- end: top li -->
          <!-- ignore empty title -->
          <!-- ignore empty title -->
          <!-- ignore empty title -->
          <!-- ignore empty title -->
          <!-- start: top li -->
          <li class="mm-item"><p><a class="mm-item-link" href="/cancer-info">NEWS &amp; RESOURCES</a></p></li>
          <!-- end: top li -->
          <!-- ignore empty title -->
          <!-- ignore empty title -->
          <!-- ignore empty title -->
          <!-- start: top li -->
          <li class="mm-item"><p><a class="mm-item-link" href="/science">FUNDING &amp; RESEARCH</a></p></li>
          <!-- end: top li -->
          <!-- ignore empty title -->
          <!-- ignore empty title -->
          <!-- ignore empty title -->
          <!-- ignore empty title -->
          <!-- start: top li -->
          <li class="mm-item"><p><a class="mm-item-link" href="/about-us">ABOUT US</a></p></li>
          <!-- end: top li -->
          <!-- ignore empty title -->
          <!-- ignore empty title -->
          <!-- ignore empty title -->
          <!-- ignore empty title -->
        </ul>
      </noscript>
      <!-- end: ul megamenu -->
    </div>
  </div><!-- .header-region -->
  <div id="breadcrumb">
    <div class="inner">
      <p class="element-invisible">You are here</p><div class="breadcrumb"><a href="/">Home</a><img src="/sites/all/themes/custom/cruk/images/breadcrumb-arrow.png" alt=""><a href="/funding-for-researchers">Funding for researchers</a><img src="/sites/all/themes/custom/cruk/images/breadcrumb-arrow.png" alt=""><a href="/funding-for-researchers/our-research-infrastructure" class="menu-node-unpublished menu-node-unpublished">Our research infrastructure</a><img src="/sites/all/themes/custom/cruk/images/breadcrumb-arrow.png" alt=""><a href="/funding-for-researchers/our-research-infrastructure/our-centre-for-drug-development" class="menu-node-unpublished menu-node-unpublished menu-node-unpublished menu-node-unpublished menu-node-unpublished menu-node-unpublished">Our Centre for Drug Development</a><img src="/sites/all/themes/custom/cruk/images/breadcrumb-arrow.png" alt="">Centre for Drug Development: Strategy and portfolio</div>    </div>
  </div>
</header>


<div class="page">
  <div class="wrapper no-gutter container">
    <main role="main" id="main-content" tabindex="-1">
      <!-- start of main content -->
                    <h1>Centre for Drug Development: Strategy and portfolio</h1>
                  
      
      
            
    <div class="grand_challenge">

      <div class="panel-row">
      <div id="panel-1" class="col-xs-12 hero-image">
        <div class="panel-content">
          
<div class="panel-pane pane-menu-tree pane-menu-centre-for-drug-development pane-menu-menu-horizontal-overview">
  
      <h2 class="pane-title">
  Centre for Drug Development</h2>



<div class="pane-content">
  <ul class="menu"><li class="first leaf menu-mlid-538196 level-1"><a href="/funding-for-researchers/our-research-infrastructure/our-centre-for-drug-development" title="" class="menu-node-unpublished">Home</a></li>
<li class="leaf active-trail active menu-mlid-538211 level-1"><a href="/funding-for-researchers/our-research-infrastructure/our-centre-for-drug-development/centre-for-drug-development-strategy-and-portfolio" title="" class="menu-node-unpublished active-trail active">Strategy &amp; portfolio</a></li>
<li class="leaf menu-mlid-538201 level-1"><a href="/funding-for-researchers/our-research-infrastructure/our-centre-for-drug-development/centre-for-drug-development-our-capabilities-and-infrastructure" title="" class="menu-node-unpublished menu-node-unpublished menu-node-unpublished">Leadership &amp; capabilities</a></li>
<li class="leaf menu-mlid-538206 level-1"><a href="/funding-for-researchers/our-research-infrastructure/our-centre-for-drug-development/centre-for-drug-development-partnership-opportunities" title="" class="menu-node-unpublished">Partnership opportunities</a></li>
<li class="last leaf menu-mlid-538216 level-1"><a href="/funding-for-researchers/our-research-infrastructure/our-centre-for-drug-development/patient-involvement" title="" class="menu-node-unpublished">Patient Involvement</a></li>
</ul></div>


</div>
<div class="panel-separator"></div>
<div class="panel-pane pane-fieldable-panels-pane pane-uuid-15c5a27b-f47d-4341-bc33-e51177d75454 pane-bundle-fieldable-panels-pane pane-promo">
  
      <h2 class="pane-title">
  Our strategic priorities</h2>



<div class="pane-content">
  <div class="fieldable-panels-pane">
    

<div class="field field-type-text-with-summary">
  
  
                <div class="field-item"><p><span class="large-font">Our ambition isÂ to accelerate the delivery of the next generation of medicines to the patients who need them.</span></p>
<p>As the world's only charity-funded drug development facility, our strategy is uniquely focused by theÂ drive for patient benefit. We are particularly interested in innovative projects, and our strengths are in:</p>
<ul class="tick-bullet">
<li>First in class therapies</li>
<li><span>First in human clinical trials</span></li>
</ul>
<p>We maintain a broad portfolio across therapeutic modalities includingÂ antibodies, imaging agents, cell therapies, vaccines and targeted small molecules.</p>
</div>
        </div>
</div>
</div>


</div>
        </div>
      </div>
    </div>
    
      <div class="panel-divide"></div>
    <div class="panel-row">
      <div id="panel-2" class="col-xs-12">
        <div class="panel-content">
          <div class="container-full
            white-panel      ">
  <div class="container">
    <div class="row">
      
<div>
  
        <h2 class="title">Our pipeline</h2>
    
  
  <div class="fieldable-panels-pane">
    

<div class="field field-type-text-with-summary">
  
  
                <div class="field-item"><p>Our development portfolio contains 12 small molecules and 12 biotherapeutic agents. Browse the agents below</p>
<div class="more"><a href="/sites/default/files/cdd_pipeline_may_2025_0.pdf">Download a copy of the pipeline</a></div>
<div class="more">Â </div>
<div class="more">
<h1>Biologics</h1>
<table border="2" cellpadding="2" cellspacing="2">
<tr>
<th>
<p class="rteleft"><strong>Â Agent (Trial)</strong></p>
</th>
<th>
<p class="rteleft"><strong>Â Target orÂ  Â Technology</strong></p>
</th>
<th>
<p class="rteleft"><strong>Â Partnerships</strong></p>
</th>
<th>
<p class="rteleft"><strong>Â Indications</strong></p>
</th>
<th>
<p class="rteleft"><strong>Â Stage</strong></p>
</th>
</tr>
<tr>
<td><a href="https://www.cancerresearchhorizons.com/news-and-events/our-news/cancer-research-uk-and-novalgen-collaborate-advance-t-cell-engager-clinic">NVG222 solid</a></td>
<td>Â BITE<br>
			Â ROR1, CD3</td>
<td><a href="https://www.novalgen.com/">NovalGen</a></td>
<td>Â Solid tumours</td>
<td>Â Exploratory</td>
</tr>
<tr>
<td><a href="https://www.cancerresearchhorizons.com/news-and-events/our-news/cancer-research-uk-cytovation-and-norwegian-cancer-society-collaborate">CY101</a></td>
<td>Peptide<br>
			Â Wnt, beta-catenin</td>
<td><a href="https://www.cytovation.com/">Cytovation</a><br>
			<a href="https://kreftforeningen.no/en/">Norwegian Cancer Society</a></td>
<td>Adrenocortical carcinoma</td>
<td>Preclinical</td>
</tr>
<tr>
<td><a href="https://www.cancerresearchhorizons.com/news-and-events/our-news/cancer-research-uk-and-kisoji-partner-for-first-naked-antibody">KJ103</a></td>
<td>Â Antibody<br>
			Â TROP2</td>
<td><a href="https://www.kisojibiotech.com/">KisoJi Biotechnology</a></td>
<td>Â Solid tumours</td>
<td>Â Preclinical</td>
</tr>
<tr>
<td><a href="https://www.cancerresearchhorizons.com/news-and-events/our-news/cancer-research-uk-and-novalgen-collaborate-advance-t-cell-engager-clinic">NVG222 haematology</a></td>
<td>Â BITE<br>
			Â ROR1, CD3</td>
<td><a href="https://www.novalgen.com/">NovalGen</a></td>
<td>Â Lymphoma</td>
<td>Â Trial Setup</td>
</tr>
<tr>
<td><a href="/about-cancer/find-a-clinical-trial/a-trial-looking-at-aleta-001-after-car-t-cell-treatment-for-b-cell-non-hodgkin-lymphoma">ALETA001</a></td>
<td>Â Protein<br>
			Â CD19, CD20</td>
<td><a href="http://www.aletabio.com/">Aleta Biotherapeutics</a></td>
<td>Â Lymphoma</td>
<td>Â Phase 1/2</td>
</tr>
<tr>
<td><a href="/about-cancer/find-a-clinical-trial/a-trial-of-hmbd-001-for-solid-cancers-that-have-spread">HMBD001</a></td>
<td>Â Antibody<br>
			Â HER3</td>
<td><a href="https://hummingbirdbioscience.com/">Hummingbird Bioscience</a></td>
<td>Â HER3 positive solid tumours, prostate</td>
<td>Â Phase 1/2 (closed in follow up)</td>
</tr>
<tr>
<td><a href="/about-cancer/find-a-clinical-trial/a-trial-looking-at-a-drug-called-ucb4594-for-cancer-that-has-spread">UCB4594</a></td>
<td>Â Antibody<br>
			Â HLA-G1</td>
<td><a href="https://www.ucb.com/">UCB</a></td>
<td>Â Solid tumours</td>
<td>Â Phase 1/2</td>
</tr>
<tr>
<td><a href="https://clinicaltrials.gov/study/NCT04908111">VTP600 (MAGE</a>)</td>
<td>Â Vaccine<br>
			Â MAGE3,<br>
			Â NY-ESO-1</td>
<td><a href="https://www.barinthusbio.com/">Barinthus Biotechnology</a><br>
			<a href="https://www.ludwig.ox.ac.uk/">Ludwig InstituteÂ for Cancer Research</a></td>
<td>Â Lung</td>
<td>
<p>Â Phase 1/2 (closed in follow up)</p>
</td>
</tr>
<tr>
<td><a href="/about-cancer/find-a-clinical-trial/a-trial-of-targeted-treatment-for-rare-cancers-that-have-spread-determine">Atezolizumab (DETERMINE)</a></td>
<td>Â Antibody<br>
			Â PDL1</td>
<td><a href="https://www.manchester.ac.uk/">University of Manchester</a><br>
			<a href="https://www.roche.com/">Roche</a></td>
<td>Â Rare paediatric, TYA &amp; adult cancer</td>
<td>Â Phase 2</td>
</tr>
<tr>
<td><a href="/about-cancer/find-a-clinical-trial/a-trial-looking-at-ginisortamab-for-pancreatic-cancer-that-has-spread">Ginisortamab</a></td>
<td>Â Antibody<br>
			Â Gremlin1</td>
<td><a href="https://www.ucb.com/">UCB</a><br>
			<a href="https://kreftforeningen.no/en/">Norwegian Cancer Society</a></td>
<td>Â Pancreatic</td>
<td>Â Phase 2</td>
</tr>
<tr>
<td><a href="/about-cancer/find-a-clinical-trial/a-trial-of-targeted-treatment-for-rare-cancers-that-have-spread-determine">Trastuzumab + Pertuzumab (DETERMINE)</a></td>
<td>Â Antibody combi<br>
			Â HER2</td>
<td><a href="https://www.manchester.ac.uk/">University of Manchester</a><br>
			<a href="https://www.roche.com/">Roche</a></td>
<td>Â Rare paediatric, TYA &amp; adult cancer</td>
<td>Â Phase 2</td>
</tr>
</table>
<p>Â </p>
<h1>Small Molecules</h1>
<table border="2" cellpadding="2" cellspacing="2">
<tr>
<th>
<p class="rteleft"><strong>Â Agent (Trial)</strong></p>
</th>
<th>
<p class="rteleft"><strong>Â TargetÂ </strong></p>
</th>
<th>
<p class="rteleft"><strong>Â Partnerships</strong></p>
</th>
<th>
<p class="rteleft"><strong>Â Indications</strong></p>
</th>
<th>
<p class="rteleft"><strong>Â Stage</strong></p>
</th>
</tr>
<tr>
<td>
<p><a href="https://www.isrctn.com/ISRCTN11160449">BT1718</a></p>
</td>
<td>Â MT1-MMP</td>
<td><a href="https://www.bicycletherapeutics.com/">Bicycle Therapeutics</a></td>
<td>Â Lung</td>
<td>Â Phase 1/2 (closed)Â </td>
</tr>
<tr>
<td>
<p><a href="/about-cancer/find-a-clinical-trial/a-trial-looking-at-htl0039732-and-other-cancer-drugs-for-solid-tumours-that-have-spread">HTL0039732</a></p>
</td>
<td>Â EP4</td>
<td><a href="https://www.nxera.life/">Nxera</a></td>
<td>Â Solid tumours, colorectal, prostate, gastric, oesophageal, renal</td>
<td>Â Phase 1/2</td>
</tr>
<tr>
<td>
<p><a href="/about-cancer/find-a-clinical-trial/a-trial-looking-at-ly3143921-hydrate-for-advanced-cancer">LY3143921</a></p>
</td>
<td>Â Cdc7</td>
<td><a href="https://www.lilly.com/">Lilly</a></td>
<td>Â Solid tumours</td>
<td>Â Phase 1Â (closed)</td>
</tr>
<tr>
<td>
<p><a href="/about-cancer/find-a-clinical-trial/a-trial-of-tt-702-for-solid-tumours-that-have-spread-curate">TT702 (CURATE)</a></p>
</td>
<td>Â AdenosineÂ  Â A2BRÂ  Â </td>
<td><a href="https://teontherapeutics.com/">Teon Therapeutics</a></td>
<td>Â Solid tumours</td>
<td>Â Phase 1/2</td>
</tr>
<tr>
<td><a href="/about-cancer/find-a-clinical-trial/a-trial-of-targeted-treatment-for-rare-cancers-that-have-spread-determine">Alectinib (DETERMINE)</a></td>
<td>
<p>Â ALK, TK1</p>
</td>
<td><a href="https://www.manchester.ac.uk/">University of Manchester</a><br>
			<a href="https://www.roche.com/">Roche</a></td>
<td>Â Rare paediatric, TYA &amp; adult cancerÂ Â </td>
<td>Â Phase 2</td>
</tr>
<tr>
<td><a href="/about-cancer/find-a-clinical-trial/a-trial-of-targeted-treatment-for-rare-cancers-that-have-spread-determine">Capmatinib (DETERMINE)</a></td>
<td>cMET, HGFR</td>
<td><a href="https://www.manchester.ac.uk/">University of Manchester</a><br>
			<a href="https://www.novartis.com/">Novartis</a></td>
<td>Â Rare adult cancer</td>
<td>Â Phase 2</td>
</tr>
<tr>
<td><a href="/about-cancer/find-a-clinical-trial/a-trial-of-targeted-treatment-for-rare-cancers-that-have-spread-determine">Entrectinib (DETERMINE)</a></td>
<td>Â ROS1, TRK,Â  Â ALKÂ </td>
<td><a href="https://www.manchester.ac.uk/">University of Manchester</a>Â  Â  Â  Â Â <br>
			<a href="https://www.roche.com/">Roche</a></td>
<td>Â Rare paediatric, TYA &amp; adult cancerÂ </td>
<td>Â Phase 2</td>
</tr>
<tr>
<td><a href="/about-cancer/find-a-clinical-trial/a-trial-of-targeted-treatment-for-rare-cancers-that-have-spread-determine">Vemurafenib + Cobimetinib (DETERMINE)</a>Â </td>
<td>Â BRAF, MAP,Â  Â MEKÂ  Â </td>
<td><a href="https://www.manchester.ac.uk/">University of Manchester</a><br>
			<a href="https://www.roche.com/">Roche</a></td>
<td>Â Rare adult cancer</td>
<td>Â Phase 2</td>
</tr>
</table>
<p>Â </p>
<p>Â  Â  Â There are three other undisclosed programmes in development: a small molecules combination, a protein degrader and a bispecific antibody.Â </p>
</div>
</div>
        </div>
</div>

  </div>
    </div>
  </div>
</div>
        </div>
      </div>
    </div>
  
  
      <div class="panel-divide"></div>
    <div class="panel-row">
      <div id="panel-5" class="col-xs-12">
        <div class="panel-content">
          <div class="panel-pane pane-fieldable-panels-pane pane-current-61351 white-panel">
  
      
  
  <div class="pane-content">
    <h2 class="content-panels-pane-header">Portfolio news</h2><div class="content-panels-pane-body"><div class="content-panels-pane-image"><img src="/sites/default/files/cruk_cdd_cmyk_2023_5.jpg" alt="CDD logo"></div><div class="content-panels-pane-body-copy"><h3>International partnerships are needed to develop new cancer treatments</h3>
<p>May 2025<br>
On International Clinical Trials Day <a href="https://www.linkedin.com/posts/larserwig_cancerresearch-internationalclinicaltrialsday-activity-7330606195642130435-Ibar/?utm_source">Lars Erwig</a>, Director of our Centre for Drug Development, talks to Drug Discovery World about developing treatments for rare cancers and the need for international collaboration with non-profits to fund more clinical trials while also facilitating patient recruitment. Our partnerships with the Norwegian Cancer Society (<a data-test-app-aware-link="" href="https://www.linkedin.com/company/kreftforeningen-norwegian-cancer-society/" tabindex="0" target="_self">Kreftforeningen</a>) and the Dutch Cancer Society (<a data-test-app-aware-link="" href="https://www.linkedin.com/company/kwf-kankerbestrijding/" tabindex="0" target="_self">KWF Kankerbestrijding</a>) do just that, recently treating our first patients outside the UK.</p>
<div class="more"><a href="https://www.ddw-online.com/we-need-international-partnerships-to-get-new-cancer-treatments-into-the-clinic-35031-202505/">Discover more</a></div>
</div></div><div class="content-panel-separator"></div><div class="content-panels-pane-body"><div class="content-panels-pane-image"><img src="/sites/default/files/1744794686047_0.png" alt="pat and lars"></div><div class="content-panels-pane-body-copy"><h3>Interview with Pat LoRusso AACR President 2025</h3>
<p>April 2025<br>
<a href="https://www.linkedin.com/in/patricia-lorusso-b000729b/">Patricia LoRusso</a>,Â Chair of our New Agents Committee, in conversation withÂ <a href="https://www.linkedin.com/posts/larserwig_patricia-lorusso-in-conversation-with-activity-7318568093260152833-bgqq?utm_source=" id="ember159">Lars Erwig</a>, Director of our Centre for Drug Development. She talks about her journey in cancer drug development, the mentors who shaped her career and how she became AACR President for 2025.Â Read the article to discover Patâs inspiring career and what to watch out for at this yearâs AACR Annual Meeting.</p>
<div class="more"><a href="https://news.cancerresearchuk.org/2025/04/15/from-inner-city-detroit-to-aacr-president/" target="_blank">Discover more</a></div>
</div></div><div class="content-panel-separator"></div><div class="content-panels-pane-body"><div class="content-panels-pane-image"><img src="/sites/default/files/nature_1.jpg" alt="nature"></div><div class="content-panels-pane-body-copy"><h3>New class of antibody shows promise for cancer patients</h3>
<p>April 2025<br>
MOv18 IgE is a novel class of antibody developed by researchers at <a href="https://www.kcl.ac.uk/news/trial-shows-promise-for-new-antibody-cancer-treatment">King's College London</a>Â that targetsÂ the folate receptor alpha antigen. Our Centre for Drug Development funded and supported the preclinical development of MOv18 IgE, then funded, sponsored and conducted <a href="https://clinicaltrials.gov/study/NCT02546921">the first in class Phase I clinical trial</a>Â led by Professor James Spicer at Guy's and St Thomas' Clinical Research Facility. A new paper sheds light on how treatment with MOv18 reactivates patients immune cells to fight ovarian cancer.Â Read more about it in Nature Communications.</p>
<div class="more"><a href="https://www.nature.com/articles/s41467-025-57870-y" target="_blank">Discover more</a></div>
</div></div><div class="content-panel-separator"></div><div class="content-panels-pane-body"><div class="content-panels-pane-image"><img src="/sites/default/files/sky_news_determine_pt_1.jpg" alt="sky news determine"></div><div class="content-panels-pane-body-copy"><h3>Patient finds hope with CDD's DETERMINE trial</h3>
<p>February 2025<br>
After her cancer treatment stopped working, Pamela Garner-JonesÂ matched to a treatment on ourÂ <a href="/about-cancer/find-a-clinical-trial/a-trial-of-targeted-treatment-for-rare-cancers-that-have-spread-determine">DETERMINE</a>Â trial via the TARGET National study, a molecular profiling programme that identifies mutations in certain genes. The results have been life-changing, with Pamela's tumours shrinking by two-thirds and her symptoms improving. Studies and trials like DETERMINE and TARGET National are paving the way for personalised cancer treatments, which can improve outcomes and cause fewer side effects, offering new hope and quality of life to patients.</p>
<div class="more"><a href="https://bit.ly/3Qx8crn" target="_blank">Watch Pamela's story here</a></div>
<div class="more"><a href="http://www.cruk.org/determine" target="_blank">Discover more about DETERMINE</a></div>
</div></div><div class="content-panel-separator"></div><div class="content-panels-pane-body"><div class="content-panels-pane-image"><img src="/sites/default/files/www.pharmiweb_0.jpg" alt="cytovation logo"></div><div class="content-panels-pane-body-copy"><h3>CDD, the Norwegian Cancer Society and Cytovation collaborate to advanceÂ rare cancer treatment</h3>
<p>January 2025<br>
Cancer Research UK,Â <a href="https://www.cytovation.com/">Cytovation</a>Â and theÂ <a href="https://kreftforeningen.no/en/">Norwegian Cancer Society</a>Â (NCS) signed an agreement to take Cytovation's lead asset, into a multi-national clinical trial. CY101 is a bifunctional peptideÂ thatÂ targets and destroys cancer cells triggering an immune response while also inhibiting Wnt/beta-catenin, a key driver of immunotherapy resistance. The trial will treat people with adrenocortical cancer (ACC), a rare and aggressive cancer with limited treatment options and an urgent need for new therapies. Two people with ACC showed a clear clinical benefit in a previous trial of CY101. The trial will be developed, sponsored and managed by our Centre for Drug Development withÂ NCS providing co-funding to support the trial.</p>
<div class="more"><a href="https://www.cancerresearchhorizons.com/news-and-events/our-news/cancer-research-uk-cytovation-and-norwegian-cancer-society-collaborate" target="_blank">Discover more</a></div>
</div></div><div class="content-panel-separator"></div><div class="content-panels-pane-body"><div class="content-panels-pane-image"><img src="/sites/default/files/20f1_kisoji_20biotechnology_20inc_5b3575f1.png" alt="kisoji logo"></div><div class="content-panels-pane-body-copy"><h3>CDD and KisoJi partner to advance first naked TROP2 antibody into the clinic</h3>
<p>October 2024<br>
Cancer Research UK and <a href="https://www.kisojibiotech.com/en/">KisoJi Biotechnology</a>Â signed a landmark agreement to bring Kisoji's lead asset into a first in human clinical trial. KJ103 is a naked anti-TROP2 antibody created by Kisoji using their proprietary technology.Â The trial will treat people with TROP2 expressing tumours which include colorectal, head &amp; neck, ovarian, breast and bladder cancers. The trial will be developed, sponsored and managed by our Centre for Drug Development and led by Professor Christian Ottensmeier at <a href="https://www.clatterbridgecc.nhs.uk/">The Clatterbridge Cancer Centre</a>Â in Liverpool.</p>
<div class="more"><a href="https://www.cancerresearchhorizons.com/news-and-events/our-news/cancer-research-uk-and-kisoji-partner-for-first-naked-antibody" target="_blank">Discover more</a></div>
</div></div><div class="content-panel-separator"></div><div class="content-panels-pane-body"><div class="content-panels-pane-image"><img src="/sites/default/files/christie_nurse_n.jpg" alt="christie nurse"></div><div class="content-panels-pane-body-copy"><h3>First patient dosed in CDD first in human trial of new immunotherapy</h3>
<p>October 2024<br>
The first patient has been treated inÂ <a href="/about-cancer/find-a-clinical-trial/a-trial-looking-at-a-drug-called-ucb4594-for-cancer-that-has-spread">our trial of HLA-G antibody UCB4594</a>, the second trial in our collaboration withÂ <a href="https://www.ucb.com/">UCB</a>. UCB4594 will be given to people with advanced cancer to prime their immune system to attack their cancer. Our Centre for Drug Development is sponsoring and managing the trial, which is led by Professor Fiona Thistlethwaite at theÂ <a href="https://www.christie.nhs.uk/">Christie NHS Foundation Trust</a>Â in Manchester with other UK sites to follow.</p>
<div class="more"><a href="https://www.cancerresearchhorizons.com/news-and-events/our-news/cancer-research-uk-announces-dosing-first-patient-UCB4594-trial" target="_blank">Discover more</a></div>
</div></div><div class="content-panel-separator"></div><div class="content-panels-pane-body"><div class="content-panels-pane-image"><img src="/sites/default/files/novalgen-2jpg_0.jpg" alt="novalgen logo"></div><div class="content-panels-pane-body-copy"><h3>CDD and NovalGen collaborate to advance T cell engager into the clinic</h3>
<p>October 2024<br>
Cancer Research UK andÂ <a href="https://www.novalgen.com/">NovalGenÂ </a>a pioneering clinical stage immunology company, announce a collaboration to bring NovalGen's next generation T cell engager into two first in human clinical trials. NVG222 is a bispecific T cell engager, targeting ROR1 and CD3, with an in-built autoregulation technology to mitigate toxicity and improve effectiveness for treating people with blood cancer or solid tumours. The trials will be developed, sponsored and managed by our Centre for Drug Development and led by Dr William Townsend atÂ <a href="https://www.uclh.nhs.uk/">University College London Hospitals</a>Â and Professor James Spicer at <a href="https://www.guysandstthomas.nhs.uk/">Guy's and St Thomas'</a>.</p>
<div class="more"><a href="https://www.cancerresearchhorizons.com/news-events/cancer-research-uk-and-novalgen-collaborate-advance-t-cell-engager-clinic" target="_blank">Discover more</a></div>
</div></div><div class="content-panel-separator"></div><div class="content-panels-pane-body"><div class="content-panels-pane-image"><img src="/sites/default/files/esmo-congress-2024-1000x250_i1920_0.jpg" alt="esmo24"></div><div class="content-panels-pane-body-copy"><h3>CDD's trial of Nxera's cancer immunotherapy at ESMO</h3>
<p>September 2024<br>
<a href="/about-cancer/find-a-clinical-trial/a-trial-looking-at-htl0039732-and-other-cancer-drugs-for-solid-tumours-that-have-spread">Our trialÂ </a>ofÂ <a href="https://www.nxera.life/">Nxera's</a>Â novel EP4 antagonist HTL0039732 led by Dr Bristi Basu at theÂ <a href="https://www.ecmcnetwork.org.uk/cambridge">Cambridge Experimental Cancer Medicine Centre</a>Â was presented at the European Society for Medical Oncology Congress in Barcelona (ESMO 2024).Â  Read the posterÂ <a href="/Posters%20-%20ESMO%20Congress%202024%20%28ctimeetingtech.com%29">here</a>.</p>
<div class="more"><a href="https://www.cancerresearchhorizons.com/news-and-events/our-news/cancer-research-uk-present-phase-1/2a-clinical-trial-cancer-immunotherapy" target="_blank">Discover more</a></div>
</div></div><div class="content-panel-separator"></div><div class="content-panels-pane-body"><div class="content-panels-pane-image"><img src="/sites/default/files/cruk_cdd_cmyk_2023_3.jpg" alt="CDD logo"></div><div class="content-panels-pane-body-copy"><h3>Making a real difference in cancer</h3>
<p>September 2024<br>
Lars Erwig, our Director of Drug Development, talks to The Medicine Maker about developing treatments for rare cancers and the need for pharma companies to increase collaboration with non-profits to deliver the best outcomes for patients.Â </p>
<div class="more"><a href="//themedicinemaker.com/discovery-development/lets-make-a-real-difference-in-cancer">Discover more</a></div>
</div></div><div class="content-panel-separator"></div><div class="content-panels-pane-body"><div class="content-panels-pane-image"><img src="/sites/default/files/banner-aoau-ward_0.jpg" alt="ward pic"></div><div class="content-panels-pane-body-copy"><h3>First patient on CDD Phase II trial of new pancreatic drug ginisortamab</h3>
<p>August 2024<br>
The first patient has been treated inÂ <a href="/about-cancer/find-a-clinical-trial/a-trial-looking-at-ginisortamab-for-pancreatic-cancer-that-has-spread">our trial of UCB's first in class Gremlin-1 targeted antibody ginisortamab</a>,Â part of our collaboration withÂ <a href="https://www.ucb.com/">UCB</a>. Ginisortamab will be given with standard chemotherapy to people with advanced pancreatic cancer. Our Centre for Drug Development is sponsoring and managing the trial, which is led by Professor Jeff Evans at theÂ <a href="https://www.beatson.scot.nhs.uk/">Beatson West of Scotland Cancer Centre</a>Â in GlasgowÂ with other sites across the UK'sÂ <a href="https://www.ecmcnetwork.org.uk/">Experimental Cancer Medicine Network</a>Â and in Europe to follow.Â </p>
<div class="more"><a href="https://www.cancerresearchhorizons.com/news-events/cancer-research-uk-announces-dosing-first-patient-phase-2-trial-ginisortamab-therapy" target="_blank">Discover more</a></div>
</div></div><div class="content-panel-separator"></div><div class="content-panels-pane-body"><div class="content-panels-pane-image"><img src="/sites/default/files/lars_erwig_0.jpg" alt="lars erwig"></div><div class="content-panels-pane-body-copy"><h3>Beyond Borders: going global with clinical trials</h3>
<p>May 2024<br>
Our Director of Drug Development, Lars Erwig, talks about the need for global collaboration in clinical trials and international partnerships to pool expertise, resources and patients.</p>
<div class="more"><a href="https://www.cancerresearchhorizons.com/news-features/our-blog/going-global-clinical-trials">Discover more</a></div>
</div></div><div class="content-panel-separator"></div><div class="content-panels-pane-body"><div class="content-panels-pane-image"><img src="/sites/default/files/norwegian-cancer-society-ncs-logo-vector.png" alt="NCS logo"></div><div class="content-panels-pane-body-copy"><h3>CDD and the Norwegian Cancer Society partner to bring more novel treatments into the clinic</h3>
<p>March 2024<br>
Cancer Research UK and <a href="https://kreftforeningen.no/en/">Norwegian Cancer Society</a>, two leading cancer research charities, announce a new multi-project strategic partnership to maximise our unique drug development capabilities to benefit people affected by cancer.Â  Under this international partnership NCS will share funding and expertise to accelerate development of new cancer treatmentsÂ into early phase trials with our Centre for Drug Development.Â </p>
<div class="more"><a href="https://www.cancerresearchhorizons.com/news/cancer-research-uk-and-norwegian-cancer-society-enter-partnership-broaden-early-phase-trial" target="_blank">Discover more</a></div>
</div></div><div class="content-panel-separator"></div><div class="content-panels-pane-body"><div class="content-panels-pane-image"><img src="/sites/default/files/large-pha_65i0479_0.jpg" alt="patient pic"></div><div class="content-panels-pane-body-copy"><h3>First patient dosed in CDD Phase I trial of Aleta Biotherapeutics' CAR T cell engager</h3>
<p>February 2024<br>
<a href="https://clinicaltrials.gov/study/NCT06045910">Our trial of first in class drug ALETA001</a> has treated the first patient. The trial is treating people with B-cell lymphoma whose disease has progressed after receiving CD19 CAR T-cell therapy, offering a new therapy forÂ people with limited treatment options. The trial is managed, run and Sponsored by CDD and led by Dr Sridhar Chaganti atÂ <a href="https://www.uhb.nhs.uk/">University HospitalÂ Birmingham</a>. The trial is also treating people in Cambridge, Manchester, Leeds and London.</p>
<div class="more"><a href="https://www.cancerresearchhorizons.com/news/aleta-biotherapeutics-and-cancer-research-uks-centre-drug-development-announce-first-patient" target="_blank">Discover more</a></div>
</div></div><div class="content-panel-separator"></div><div class="content-panels-pane-body"><div class="content-panels-pane-image"><img src="/sites/default/files/gavin_image_0.jpg" alt="Gavin Halbert"></div><div class="content-panels-pane-body-copy"><h3>Director of our Formulation Unit awarded OBE</h3>
<p>January 2024<br>
CDD is very proud to announce that the work and research of Professor Gavin Halbert, the long time Director of ourÂ <a href="https://www.strath.ac.uk/research/subjects/pharmacybiomedicalsciences/cancerresearchukfomulationunit/">Formulation Unit based at the University of Strathclyde</a>, has been recognised in the New Years Honours with an OBE. The CRUK Formation Unit was set up in the 1980s to provide drug formulation and manufacture for CRUK's early clinical trials of new experimental cancer treatments. Over the years Gavin's team at the Unit has worked on drugs such as temozolomide (approved for brain cancer in 2001), abiraterone (approved for prostate cancer in 2011) and rucaparib (approved for ovarian cancer in 2018), ensuring these new treatments were safe to be given to patients for the first time in CDD's clinical trials and smoothing their pathway towards approval for every day use in the clinic, ultimately benefiting many thousands of people worldwide.</p>
<div class="more"><a href="https://news.cancerresearchuk.org/2024/01/05/cancer-research-uk-celebrates-new-year-honours-2024/" target="_blank">Discover more</a></div>
</div></div><div class="content-panel-separator"></div><div class="content-panels-pane-body"><div class="content-panels-pane-image"><img src="/sites/default/files/cruk_cdd_cmyk_2023_0.jpg" alt="CDD logo"></div><div class="content-panels-pane-body-copy"><h3>CRUK appoints new Director of CDD</h3>
<p>December 2023<br>
CRUK appoints industry veteran Dr Lars Erwig as the new Director for our Centre for Drug Development, the world's only charity-funded drug development facility.</p>
<div class="more"><a href="https://www.cancerresearchhorizons.com/news/cancer-research-uk-appoints-new-director-lead-its-centre-drug-development" target="_blank">Discover more</a></div>
</div></div><div class="content-panel-separator"></div><div class="content-panels-pane-body"><div class="content-panels-pane-image"><img src="/sites/default/files/guardant.png" alt="guardant logo"></div><div class="content-panels-pane-body-copy"><h3>CRUK and Guardant collaborate to advance clinical research and development activities</h3>
<p>December 2023<br>
Cancer Research UK, <a href="https://www.cancerresearchhorizons.com/">Cancer Research Horizons</a> and <a href="https://guardanthealth.com/">Guardant Health Inc</a>, a leading precision oncology company, announce a collaboration to explore opportunities to accelerate discovery and development of cancer drugs and diagnostics, focusing on CDD's clinical trials and other research collaborations.</p>
<div class="more"><a href="https://www.cancerresearchhorizons.com/news/cancer-research-uk-and-guardant-health-launch-collaboration-advance-cancer-research-and" target="_blank">Discover more</a></div>
</div></div><div class="content-panel-separator"></div><div class="content-panels-pane-body"><div class="content-panels-pane-image"><img src="/sites/default/files/kwf-logo-rgb-1024x277.png" alt="KWF logo"></div><div class="content-panels-pane-body-copy"><h3>CDD and KWF partner to advance novel treatments into the clinic</h3>
<p>November 2023<br>
Cancer Research UK and <a href="https://www.kwf.nl/">KWF Dutch Cancer Society</a>, two of the worlds largest charitable funders of cancer research, announce a new multi-project strategic partnership to advance promising therapeutic agents for cancer through early clinical development.Â This international collaboration gives us a global outlook on cancer, broadening the potential benefit to patients worldwide.</p>
<div class="more"><a href="https://www.cancerresearchhorizons.com/news/cancer-research-uk-and-kwf-dutch-cancer-society-enter-partnership-bring-multiple-drugs" target="_blank">Discover more</a></div>
</div></div><div class="content-panel-separator"></div><div class="content-panels-pane-body"><div class="content-panels-pane-image"><img src="/sites/default/files/esmo-2023-2.jpg" alt="ESMO23"></div><div class="content-panels-pane-body-copy"><h3>Progress from CDD's novel antibody trial</h3>
<p>October 2023<br>
Clinical data from our trial of Hummingbirdâs anti-HER3 antibodyÂ <a href="/about-cancer/find-a-clinical-trial/a-trial-of-hmbd-001-for-solid-cancers-that-have-spread">HMBD001 for the treatment of people with HER3 driven cancer</a>Â led by Professor Johann de Bono at <a href="https://www.royalmarsden.nhs.uk/">the Royal Marsden NHS Foundation Trust</a> were presented at the European Society for Medical Oncology Congress (ESMO 2023).</p>
<div class="more">
<p><a href="https://hummingbirdbioscience.com/hummingbird-bioscience-announces-positive-phase-i-clinical-data-for-hmbd-001-monotherapy-trial-at-the-european-society-for-medical-oncology-congress-2023/" target="_blank">Discover more</a></p>
</div>
</div></div><div class="content-panel-separator"></div><div class="content-panels-pane-body"><div class="content-panels-pane-image"><img src="/sites/default/files/webimage-8ffffce4-f17c-4021-b56951d6349f573b_1.png" alt="nurses pic"></div><div class="content-panels-pane-body-copy"><h3>People with rare cancers given hope by CDD's DETERMINE trial</h3>
<p>October 2023<br>
Read in The Observer about 2 patients onÂ <a href="http://www.cruk.org/determine">DETERMINE</a>, our large multi-drug precision medicine trial, who have seen their tumours reduce following treatment.Â DETERMINE offers people with rare cancer drugs already approved for more common cancers to see if they also work in rare cancers.Â The trial is led by Dr Matt Krebs at theÂ <a href="https://www.christie.nhs.uk/">Christie NHS Foundation Trust</a>, Dr Lynley Marshall at theÂ <a href="https://www.royalmarsden.nhs.uk/">Royal Marsden NHS Foundation Trust</a>Â and Professor Gary Middleton atÂ <a href="https://www.birmingham.ac.uk/research/ecmc/index.aspx">Birmingham Experimental Cancer Medicine Centre</a>. DETERMINE is also treating people in Belfast, Glasgow,Â Edinburgh, Cardiff, Newcastle, Liverpool, Sheffield, Leicester, Bristol, Cambridge, Oxford, Southampton and London.</p>
<div class="more"><a href="https://www.theguardian.com/science/2023/oct/14/patients-with-rare-cancers-given-hope-by-uk-led-drug-match-trial" target="_blank">Discover more</a></div>
</div></div><div class="content-panel-separator"></div><div class="content-panels-pane-body"><div class="content-panels-pane-image"><img src="/sites/default/files/webimage-5c7aca7a-919e-4dc8-b9d7b12bc6520d25_1.jpg" alt="nurses pic"></div><div class="content-panels-pane-body-copy"><h3>First patient dosed in CDD trial of new cancer immunotherapy</h3>
<p>August 2023<br>
Cancer Research UK andÂ <a href="https://soseiheptares.com/">Sosei Heptares</a>Â announceÂ the first patient has been dosed with Sosei's cancer immunotherapy HTL0039732, a novel EP4Â antagonist.Â Our Centre for Drug Development is sponsoring and managing the trial, <a href="https://crukcambridgecentre.org.uk/news/first-patient-recruited-cambridge-novel-cancer-immunotherapy-trial?">which is led by Dr Bristi Basu</a> at theÂ <a href="https://www.ecmcnetwork.org.uk/cambridge">Cambridge Experimental Cancer Medicine Centre</a>Â and Dr Debashis Sarker atÂ <a href="https://www.guysandstthomas.nhs.uk/">Guys and St Thomas' London</a>Â with otherÂ <a href="https://www.ecmcnetwork.org.uk/">Experimental Cancer Medicine Network</a>Â sites in Manchester, Cardiff and Liverpool.</p>
<div class="more"><a href="https://www.cancerresearchhorizons.com/news/sosei-heptares-and-cancer-research-uk-announce-dosing-first-patient-phase-1/2a-trial-cancer" target="_blank">Discover more</a></div>
</div></div><div class="content-panel-separator"></div><div class="content-panels-pane-body"><div class="content-panels-pane-image"><img src="/sites/default/files/nature_1.png" alt="Nature logo"></div><div class="content-panels-pane-body-copy"><h3>New class of antibody shows promise for cancer patients</h3>
<p>July 2023<br>
MOv18 IgE is a novel class of antibody developed by researchers at <a href="https://www.kcl.ac.uk/news/trial-shows-promise-for-new-antibody-cancer-treatment">King's College London</a>Â that targetsÂ the folate receptor alpha antigen. Our Centre for Drug Development funded and supported the preclinical development of MOv18 IgE, then funded, sponsored and conducted <a href="https://clinicaltrials.gov/study/NCT02546921">the first in class Phase I clinical trial</a>Â led by Professor James Spicer at King's College London. Read more about it in <a href="https://www.nature.com/articles/s41467-023-39679-9">Nature Communications</a>.</p>
<div class="more"><a href="https://www.cancerresearchhorizons.com/news/new-class-antibody-drug-shows-promise-cancer-patients" target="_blank">Discover more</a></div>
</div></div><div class="content-panel-separator"></div><div class="content-panels-pane-body"><div class="content-panels-pane-image"><img src="/sites/default/files/lineage_2023_rgb_jpg_1740x360.jpg" alt="lineage logo"></div><div class="content-panels-pane-body-copy"><h3>CRUK and Lineage Cell Therapeutics report the results of CDD's cancer vaccine trial</h3>
<p>July 2023<br>
We report the results of ourÂ <a href="/about-cancer/find-a-clinical-trial/a-trial-of-a-vaccine-called-ast-vac2-for-non-small-cell-lung-cancer">Phase 1 clinicalÂ trial of first in class drug VAC2</a>Â in people withÂ non-small cell lung cancer.</p>
<div class="more"><a href="https://www.cancerresearchhorizons.com/news/topline-phase-1-study-results-vac2-treatment-advanced-non-small-cell-lung-cancer?" target="_blank">Discover more</a></div>
</div></div><div class="content-panel-separator"></div><div class="content-panels-pane-body"><div class="content-panels-pane-image"><img src="/sites/default/files/prime-rose_0.jpg" alt="prime rose logo"></div><div class="content-panels-pane-body-copy"><h3>CDD joins PRIME-ROSE European consortium</h3>
<p>June 2023<br>
PRIME-ROSE, a Europe-wide consortium with 24 partners in 17 countries led by <a href="https://www.ous-research.no/home/kt/Group+members/14789">Professor Kjetil TaskÃ©n</a> and the <a href="https://www.uio.no/english/">University of Oslo</a>, aims to boost patient access to <a href="https://www.cancer.gov/publications/dictionaries/cancer-terms/def/precision-medicine">precision cancer medicine</a>Â (PCM) treatments. Our Centre for Drug Development joins as an associate partner in PRIME-ROSE to represent the UK as the lead organisation runningÂ <a href="/funding-for-researchers/our-research-infrastructure/our-centre-for-drug-development/determine-overview">DETERMINE</a>,Â our PCM trial open to adult, young adult and paediatric patients with any rare cancer.Â Our collaboration with European colleagues to harmonise trial designs and share dataÂ will help speed up assessment of these treatments to bring new life-prolonging treatment options to people with cancer.</p>
<div class="more"><a href="https://www.cancerresearchhorizons.com/news/cancer-research-uk-joins-european-precision-cancer-medicine-trial-consortium" target="_blank">Discover more</a></div>
</div></div><div class="content-panel-separator"></div><div class="content-panels-pane-body"><div class="content-panels-pane-image"><img src="/sites/default/files/ucb_logo2.png" alt="UCB logo"></div><div class="content-panels-pane-body-copy"><h3>CDD and UCB collaborate to advance novel antibodies into the clinic</h3>
<p>March 2023<br>
Cancer Research UK andÂ <a href="https://www.ucb.com/">UCB</a>, a global biopharmaceutical company, announce a clinical development collaboration to advance two of UCB's antibody candidates through clinical trials: UCB6114, a potential first in class antibody targeting gremlin-1, and UCB4594, an antibody targeting HLA-G. The trials will be developed, sponsored and managed by our Centre for Drug Development.Â </p>
<div class="more"><a href="https://www.cancerresearchhorizons.com/news/cancer-research-uk-signs-multi-project-collaboration-ucb-advance-oncology-antibody-candidates" target="_blank">Discover more</a></div>
</div></div><div class="content-panel-separator"></div><div class="content-panels-pane-body"><div class="content-panels-pane-image"><img src="/sites/default/files/hummingbird_bioscience_logobigger_0.jpg" alt="hummingbird logo"></div><div class="content-panels-pane-body-copy"><h3>Hummingbird Bioscience exercise the option to licence CDD's clinical trialÂ results</h3>
<p>March 2023<br>
Cancer Research Horizons andÂ <a href="https://hummingbirdbioscience.com/">Hummingbird Bioscience</a>Â announceÂ that Hummingbird BioscienceÂ has exercised their option to licence theÂ <a href="/about-cancer/find-a-clinical-trial/a-trial-of-hmbd-001-for-solid-cancers-that-have-spread">first in human clinical trial results of anti-HER3 antibody HMBD001</a>.Â Our Centre for Drug Development is sponsoring and managing the trial which is led by Professor Johann de Bono at theÂ <a href="https://www.royalmarsden.nhs.uk/our-consultants-units-and-wards/royal-marsden-sutton-surrey">Royal Marsden Hospital</a>Â andÂ <a href="https://www.icr.ac.uk/home">Institute of Cancer Research</a>Â with other sites in Oxford,Â NewcastleÂ andÂ Manchester.Â </p>
<div class="more"><a href="https://www.cancerresearchhorizons.com/news/hummingbird-bioscience-exercises-its-option-license-clinical-trial-results-cancer-research-uk" target="_blank">Discover more</a></div>
</div></div><div class="content-panel-separator"></div><div class="content-panels-pane-body"><div class="content-panels-pane-image"><img src="/sites/default/files/621f9140654abf384c30d640_0.png" alt="novartis logo"></div><div class="content-panels-pane-body-copy"><h3>Novartis joins CDD's DETERMINE trial for rare paediatric and adult cancers</h3>
<p>December 2022<br>
CDD launch their first major collaboration withÂ <a href="https://www.novartis.com/">Novartis</a>.Â <a href="http://www.cruk.org/determine">DETERMINE</a>,Â a large multi-drug, precision medicine platform trial for adults and children with rare cancers, was set up by CDD in collaboration withÂ <a href="https://www.manchester.ac.uk/">the University of Manchester</a> and Roche.Â Novartis is now joining as the second pharmaceutical partner to provide access to their targeted treatments for trial participants.Â </p>
<div class="more"><a href="https://www.cancerresearchhorizons.com/news/novartis-joins-cancer-research-uk-trial-rare-cancers" target="_blank">Discover more</a></div>
</div></div><div class="content-panel-separator"></div><div class="content-panels-pane-body"><div class="content-panels-pane-image"><img src="/sites/default/files/sh_logo_0.png" alt="SH logo"></div><div class="content-panels-pane-body-copy"><h3>CDD and Sosei Heptares join forces to advance cancer immunotherapy into the clinic</h3>
<p>July 2022<br>
Cancer Research UK andÂ <a href="https://soseiheptares.com/">Sosei Heptares</a>, an international biopharmaceutical company and world leader in GPCR-focussed structure-based drug design and development, announceÂ an agreement to bring Sosei's cancer immunotherapy HTL0039732, a novel selective EP4 antagonist, into a first in human clinical trial. HTL0039732 is proposed for a range of cancers including colorectal, gastro-oesophageal, prostate and head and neck cancer. The trial will be developed, sponsored and managed by our Centre for Drug Development.Â </p>
<div class="more"><a href="https://www.cancerresearchhorizons.com/news/cancer-research-uk-and-sosei-heptares-sign-agreement-advance-cancer-immunotherapy-candidate" target="_blank">Discover more</a></div>
</div></div><div class="content-panel-separator"></div><div class="content-panels-pane-body"><div class="content-panels-pane-image"><img src="/sites/default/files/stitch_logo.png" alt="stitch logo"></div><div class="content-panels-pane-body-copy"><h3>CDD partnership to help improve patients' experience of our clinical trials</h3>
<p>July 2022<br>
Our collaboration with <a href="https://www.stitchhealth.co/">Stitch</a>Â creates a unique opportunity for each patient to manage their own trial journey and for us to hear directly from patients throughout the trial. CDD worked with ourÂ patient involvement networkÂ to create a specially tailored app. People on our trials will be able to feedback their experiences and we will apply their insights to design more patient-centred clinical trials for the best possible experience for our patients.Â </p>
<div class="more"><a href="https://www.cancerresearchhorizons.com/news/cancer-research-uk-and-stitch-partner-understand-and-improve-patient-experience-clinical?utm_source=CRUKTwitter&amp;utm_medium=socialmedia&amp;utm_campaign=StitchPartnership22&amp;utm_id=StitchPartnership22" target="_blank">Discover more</a></div>
</div></div><div class="content-panel-separator"></div><div class="content-panels-pane-body"><div class="content-panels-pane-image"><img src="/sites/default/files/cancer_research_horizons_2.jpg" alt="CR Horizons"></div><div class="content-panels-pane-body-copy"><h3>CDD working in collaboration with Cancer Research HorizonsÂ </h3>
<p>April 2022<br>
Cancer Research UK's new and ambitious approach to driving innovation in the development of new treatments for patients, combines the power of academia and industry. <a href="https://www.cancerresearchhorizons.com/">Cancer Research Horizons</a> brings under one umbrella CRUKâs established drug discovery laboratories, network of world-class biology, cutting-edge technology platforms and clinical expertise, offering a unique R&amp;D portfolio. Partners gain access to our extensive network of 4,000 world-leading cancer researchers and a discovery research portfolio investment of over Â£400 million annually.</p>
<div class="more"><a href="https://www.cancerresearchhorizons.com/news/cancer-research-uk-reveals-innovation-engine-underpinned-ps400m-portfolio-cutting-edge" target="_blank">Discover more</a></div>
</div></div><div class="content-panel-separator"></div><div class="content-panels-pane-body"><div class="content-panels-pane-image"><img src="/sites/default/files/clinical_trials_landing_hero_2.jpg" alt="nurses pic"></div><div class="content-panels-pane-body-copy"><h3>CDD's CURATE trial treats the first patient</h3>
<p>March 2022<br>
Cancer Research UK andÂ <a href="https://teontherapeutics.com/">Teon Therapeutics</a>Â announce the first patientÂ has been treated in theÂ <a href="/about-cancer/find-a-clinical-trial/a-trial-of-tt-702-for-solid-tumours-that-have-spread-curate">CURATE trial</a>Â of Teonâs first in class A2BR-specific antagonist, TT702, for people with a range of difficult to treat cancers. The trial is run and sponsored by our Centre for Drug Development and led by Professor Johann de Bono atÂ <a href="https://www.royalmarsden.nhs.uk/">the Royal Marsden NHS Foundation Trust</a>Â with other sites in Manchester and Southampton.</p>
<div class="more"><a href="http://commercial.cancerresearchuk.org/cancer-research-uk-and-teon-therapeutics-announce-first-patient-dosed-clinical-trial-hard-treat?_gl=1*1xgyk3a*_gcl_au*MTcyMjcyOTUwMC4xNjk1Mjg5MjA4*_ga*MTUxOTcwMzg4LjE2Nzk0ODIwMTE.*_ga_58736Z2GNN*MTY5NzU0ODgyNC4xMjguMS4xNjk3NTQ5NzkzLjAuMC4w&amp;_ga=2.223441499.1111081850.1697461461-151970388.1679482011" target="_blank">Discover more</a></div>
</div></div><div class="content-panel-separator"></div><div class="content-panels-pane-body"><div class="content-panels-pane-image"><img src="/sites/default/files/determine_logo_lockup_aw_stacked_rgb_0.jpg" alt="Determine logo"></div><div class="content-panels-pane-body-copy"><h3>CDD partners with cancer researchers across the UK to find drugs to treat rare cancers</h3>
<p>December 2021<br>
Cancer Research UK, <a href="https://www.manchester.ac.uk/">the University of Manchester</a> and <a href="https://www.roche.com/">Roche</a>Â announce a partnership toÂ run <a href="http://www.cruk.org/determine">DETERMINE</a>, a large multi-drug, precision medicine platform trial for adults and children with rare cancers who have run out of other treatment options. DETERMINE will be sponsored and managed by our Centre for Drug Development and will use targeted treatments that are already approved for treating other cancer types. Roche will provide 7 of their targeted drugs. Other pharmaceutical partners are expected to join and contribute their drugs as the trial progresses. <a href="https://www.pharmatimes.com/news/cancer_researchers_across_the_uk_partner_in_new_trial_to_find_drugs_for_rare_cancers_1385665">Read about DETERMINE in the PharmaTimes</a>.</p>
<div class="more"><a href="http://commercial.cancerresearchuk.org/cancer-researchers-across-uk-join-forces-find-drugs-rare-cancers" target="_blank">Discover more</a></div>
</div></div><div class="content-panel-separator"></div><div class="content-panels-pane-body"><div class="content-panels-pane-image"><img src="/sites/default/files/aleta_bio_0.png" alt="Aleta logo"></div><div class="content-panels-pane-body-copy"><h3>CDD collaborate with Aleta Biotherapeutics to advanceÂ blood cancer therapy into the clinic</h3>
<p>JuneÂ 2021<br>
Cancer Research UK andÂ <a href="http://www.aletabio.com/">Aleta Biotherapeutics</a>Â signed an agreement toÂ progress the early phase clinicalÂ development of ALETA001, their CAR T-cell engager.Â ALETA001 has been developed to benefit people with B-cell lymphoma whose disease has progressed after receiving CD19 CAR T-cell therapy. Our Centre for Drug Development will develop, sponsor and conduct the first in human Phase 1/2a clinical trial, to be led by Dr Sridhar Chaganti at <a href="https://www.uhb.nhs.uk/">University Hospital Birmingham</a>.</p>
<div class="more"><a href="http://commercial.cancerresearchuk.org/aleta-biotherapeutics-and-cancer-research-uk-collaborate-advance-blood-cancer-therapy-clinic?">Discover more</a></div>
</div></div><div class="content-panel-separator"></div><div class="content-panels-pane-body"><div class="content-panels-pane-image"><img src="/sites/default/files/teon-logo.png" alt="teon logo"></div><div class="content-panels-pane-body-copy"><h3>CDD partner with Teon Therapeutics to develop new drug into the clinic</h3>
<p>December 2020<br>
<a href="https://www.teontherapeutics.com/">Teon Therapeutics</a> announceÂ a collaboration with Cancer Research UK'sÂ Centre for Drug Development to progress TT702, Teonâs first-in-class A2BR-specific antagonist, to <a href="/about-cancer/find-a-clinical-trial/a-trial-of-tt-702-for-solid-tumours-that-have-spread-curate">aÂ Phase 1/2 clinical trialÂ in prostate and other cancers</a>.Â Our Centre for Drug Development will develop, sponsor and manage theÂ clinical trial.Â </p>
<div class="more"><a href="https://www.prnewswire.com/news-releases/teon-therapeutics-announces-approval-for-collaboration-with-cancer-research-uk-301191786.html">Discover more</a></div>
</div></div><div class="content-panel-separator"></div><div class="content-panels-pane-body"><div class="content-panels-pane-image"><img src="/sites/default/files/lineage_2023_rgb_jpg_1740x360_0.jpg" alt="lineage logo"></div><div class="content-panels-pane-body-copy"><h3>Lineage Cell Therapeutics exercises its option early to CDDÂ immuno-oncology programme</h3>
<p>May 2020<br>
<a href="https://lineagecell.com/">Lineage</a> announceÂ it isÂ exercisingÂ its option to acquire data early from our Centre for Drug Development'sÂ <a href="/about-cancer/find-a-clinical-trial/a-trial-of-a-vaccine-called-ast-vac2-for-non-small-cell-lung-cancer">first in class Phase 1 trialÂ of ASTVAC2</a> (also called VAC2) in people with non-small cell lung cancer.Â Immunogenicity data from theÂ clinical trial supports the Mechanism of Action.Â Cancer Research UK will provide input on the potential use of the VAC platform in the infectious disease space to develop a vaccine against SARS-CoV-2, the virus which causes COVID-19.Â </p>
<div class="more"><a href="https://investor.lineagecell.com/news-releases/news-release-details/lineage-cell-therapeutics-announces-early-exercise-option-cancer">Discover more</a></div>
</div></div><div class="content-panel-separator"></div><div class="content-panels-pane-body"><div class="content-panels-pane-image"><img src="/sites/default/files/download_10.png" alt="vaccitech logo"></div><div class="content-panels-pane-body-copy"><h3>Partnership for first in human trial for new lung cancer immunotherapy</h3>
<p>December 2019<br>
Cancer Research UK,Â <a href="https://www.vaccitech.co.uk/">Vaccitech Oncology Limited </a>(VOLT)Â and the <a href="https://www.ludwig.ox.ac.uk/">Ludwig Institute for Cancer Research</a>Â in Oxford announce aÂ  partnership to bring <a href="/about-cancer/find-a-clinical-trial/a-trial-looking-at-a-vaccine-chemotherapy-and-an-immunotherapy-for-non-small-cell-lung-cancer">a novel immunotherapeutic vaccineÂ to people with non-small cell lung cancer</a>. The trial, to be run and sponsored by our Centre for Drug Development, will see if combiningÂ the new vaccine with standard chemotherapy and anti-PD1 drugsÂ improves the effectiveness of these treatments and also provokes a safeÂ anti-cancer immune response, improving outcomes for lung cancer patients.</p>
<div class="more"><a href="/about-us/cancer-news/press-release/2019-12-17-first-in-human-trial-for-new-lung-cancer-immunotherapy">Discover more</a></div>
</div></div><div class="content-panel-separator"></div><div class="content-panels-pane-body"><div class="content-panels-pane-image"><img src="/sites/default/files/bioinvent_logo_0.png" alt="bioinvent logo"></div><div class="content-panels-pane-body-copy"><h3>CDD sign manufacturing agreement with BioInvent</h3>
<p>October 2019<br>
HMBD-001, Hummingbird Bioscience's anti-HER3 antibody,Â is being jointly developed with our Centre for Drug DevelopmentÂ forÂ a <a href="/about-cancer/find-a-clinical-trial/a-trial-of-hmbd-001-for-solid-cancers-that-have-spread">CDD sponsored Phase 1Â clinical trial</a>.Â We signed an agreement with <a href="https://www.bioinvent.com/en">BioInvent</a>, based in Lund Sweden, toÂ manufacture theÂ antibody to GMP. ItÂ will then be passedÂ to our <a href="https://www.strath.ac.uk/research/subjects/pharmacybiomedicalsciences/cancerresearchukfomulationunit/">CRUK Formulation Unit</a>Â at the University ofÂ Strathclyde to produce the final drug that will be given to patients.</p>
<div class="more"><a href="https://www.bioinvent.com/en/press/bioinvent-signs-manufacturing-agreement-cancer-research-uk-expected-generate-approximately">Discover more</a></div>
</div></div>  </div>

  
  </div>
<div class="panel-separator"></div>
<div class="panel-pane pane-custom pane-1">
  
      <h2 class="pane-title">
  Our track record of marketed drugs</h2>



<div class="pane-content">
  <span class="title-only"></span></div>


</div>
        </div>
      </div>
    </div>
  
      <div class="panel-divide"></div>
    <div class="panel-row">
              <div id="panel-6" class="col-md-4 col-sm-12 col-xs-12">
          <div class="panel-content">
            
<div class="panel-pane pane-fieldable-panels-pane pane-uuid-fe4cb787-1277-41d3-82d1-5826d2ad0a10 pane-bundle-fieldable-panels-pane pane-promo">
  
      <h2 class="pane-title">
  Abiraterone</h2>



<div class="pane-content">
  <div class="fieldable-panels-pane">
    

<div class="field field-type-text-with-summary">
  
  
                <div class="field-item"><p>Discovered at the CRUK Cancer Therapeutics Unit at The Institute of Cancer Research, and developed by the Centre for Drug Development before licensing to Janssen Biotech, Abiraterone acetate (ZytigaÂ®) is a hormonal therapy for prostate cancer.</p>
</div>
        </div>
</div>
</div>


</div>
<div class="panel-separator"></div>
<div class="panel-pane pane-fieldable-panels-pane pane-uuid-70c54c01-1e95-4b5e-aadc-5df43e7561fc pane-bundle-fieldable-panels-pane pane-promo">
  
      <h2 class="pane-title">
  Pemetrexed</h2>



<div class="pane-content">
  <div class="fieldable-panels-pane">
    

<div class="field field-type-text-with-summary">
  
  
                <div class="field-item"><p>Pemetrexed (AlimtaÂ®) is indicated for pleural mesothelioma and non-small cell lung cancer.<br>Â <br>Â </p>
</div>
        </div>
</div>
</div>


</div>
          </div>
        </div>
      
              <div id="panel-7" class="col-md-4 col-sm-12 col-xs-12">
          <div class="panel-content">
            
<div class="panel-pane pane-fieldable-panels-pane pane-uuid-feb1447b-fb8b-438b-951a-ee0fa0d05fb7 pane-bundle-fieldable-panels-pane pane-promo">
  
      <h2 class="pane-title">
  Temozolomide</h2>



<div class="pane-content">
  <div class="fieldable-panels-pane">
    

<div class="field field-type-text-with-summary">
  
  
                <div class="field-item"><p>One of our earliest successes, discovered by CRUK-funded scientists and developed by the CDD in the 1980s and 90s,Â Temozolomide (Temodal Â®) is used worldwide as the frontline drug for glioblastoma and astrocytoma.</p>
<div class="more"><a href="/funding-for-researchers/research-features/2017-07-26-temozolomide-the-brain-tumour-superstar">Read our case study</a></div>
</div>
        </div>
</div>
</div>


</div>
<div class="panel-separator"></div>
<div class="panel-pane pane-fieldable-panels-pane pane-uuid-bdb2c98e-5f37-4406-ac83-446edc382b73 pane-bundle-fieldable-panels-pane pane-promo">
  
      <h2 class="pane-title">
  Etoposide phosphate</h2>



<div class="pane-content">
  <div class="fieldable-panels-pane">
    

<div class="field field-type-text-with-summary">
  
  
                <div class="field-item"><p>Etoposide phosphate (EtopophosÂ®) is a drug used in small cell lung cancer and testicular tumours that no longer respond to other treatments.<br>Â </p>
</div>
        </div>
</div>
</div>


</div>
          </div>
        </div>
      
              <div id="panel-8" class="col-md-4 col-sm-12 col-xs-12">
          <div class="panel-content">
            
<div class="panel-pane pane-fieldable-panels-pane pane-uuid-97d4a3a3-38d8-4fa5-abcf-4ef8ac940081 pane-bundle-fieldable-panels-pane pane-promo">
  
      <h2 class="pane-title">
  Rucaparib</h2>



<div class="pane-content">
  <div class="fieldable-panels-pane">
    

<div class="field field-type-text-with-summary">
  
  
                <div class="field-item"><p>Discovered by CRUK scientists at the Northern Institute for Cancer Research in a programme built on breakthroughs from CRUK's basic science, we progressed the early development of the PARP inhibitor Rucaparib (Rubraca<span>Â®</span>).</p>
<div class="more"><a href="/funding-for-researchers/research-features/2017-07-21-rucaparib-targeting-dna-repair-and-a-patients-perpective">Read our case study</a></div>
</div>
        </div>
</div>
</div>


</div>
<div class="panel-separator"></div>
<div class="panel-pane pane-fieldable-panels-pane pane-uuid-2f01aa9f-b049-469c-a597-2b806b83ebfe pane-bundle-fieldable-panels-pane pane-promo">
  
      <h2 class="pane-title">
  Formestane</h2>



<div class="pane-content">
  <div class="fieldable-panels-pane">
    

<div class="field field-type-text-with-summary">
  
  
                <div class="field-item"><p>Formestane (LentaronÂ®) is a selective aromatase inhibitor that was indicated for the use in breast cancer, but was subsequently superseded by third-generation inhibitors such as letrozole.</p>
</div>
        </div>
</div>
</div>


</div>
          </div>
        </div>
          </div>
  
  
  
      <div class="panel-divide"></div>
    <div class="panel-row">
      <div id="panel-12" class="col-xs-12">
        <div class="panel-content">
          
<div class="panel-pane pane-fieldable-panels-pane pane-current-30546 pane-bundle-fieldable-panels-pane pane-promo">
  
      <h2 class="pane-title">
  Contact us</h2>



<div class="pane-content">
  <div class="fieldable-panels-pane">
    

<div class="field field-type-text-with-summary">
  
  
                <div class="field-item"><p><span>We're looking to partner with leading pharmaceutical and biotechnology companies and academic scientists who require resource, capabilities or expertise to develop new agents for the treatment of cancer. </span></p>
<p><span class="button"><a href="mailto:drugdev@cancer.org.uk">Get in touch</a></span></p>
</div>
        </div>
</div>
</div>


</div>
        </div>
      </div>
    </div>
  
  
      <div class="panel-divide"></div>
    <div class="panel-row">
      <div id="panel-16" class="col-xs-12">
        <div class="panel-content">
          
<div>
  
      
  
  <div class="fieldable-panels-pane">
    

<div class="field field-type-text-with-summary">
  
  
                <div class="field-item"><style>
.horizontal-nav--desktop ul {
    padding: 0;
    margin: 0;
    border-top: none;
    border: 1px solid #e3e3e3;
    -moz-border-radius: 3px;
    -webkit-border-radius: 3px;
    border-radius: 3px;
}
</style></div>
        </div>
</div>

  </div>
        </div>
      </div>
    </div>
  
</div>
  
            <div id="mobile-nav"></div>
     <!-- end of main content -->
    </main>

    
    
  </div><!-- #wrapper -->
</div>

<footer role="contentinfo">
  <div class="container">
    <div class="footer-links">
      <div class="footer-links__list">
        <h2>Speak to a nurse</h2>
        <ul>
          <li><a href="tel://0808%20800%204040">Nurse Helpline<br>0808 800 4040</a></li>
          <li>Questions about cancer? Call freephone<br>9 to 5 Monday to Friday or <a href="/about-us/contact-us/talk-to-our-nurses?secure=true">email us</a></li>
        </ul>
      </div>

      <div class="footer-links__list">
        <h2>Quick links</h2><ul class="links"><li class="0 first"><a href="/get-involved/find-a-shop">Find local shops</a></li>
<li class="1"><a href="https://shop.cancerresearchuk.org/?utm_source=cruk_footer">Shop online</a></li>
<li class="2"><a href="/about-us/contact-us">Contact us</a></li>
<li class="3 last"><a href="/about-us/charity-jobs">Jobs</a></li>
</ul>      </div>

      <div class="footer-links__icons">
        <h2>Follow us</h2>
        <ul>
          <li>
            <a href="https://www.facebook.com/cancerresearchuk/">
              <img src="/sites/all/themes/custom/cruk/images/social_icons/facebook_icon.svg" width="40" height="40" alt="Like Cancer Research UK on Facebook">
            </a>
          </li>
          <li>
            <a href="https://twitter.com/CR_UK">
              <img src="/sites/all/themes/custom/cruk/images/social_icons/twitter_icon.svg" width="40" height="40" alt="Follow Cancer Research UK on Twitter">
            </a>
          </li>
          <li>
            <a href="https://www.instagram.com/cr_uk/">
              <img src="/sites/all/themes/custom/cruk/images/social_icons/instagram_icon.svg" width="40" height="40" alt="Follow Cancer Research UK on Instagram">
            </a>
          </li>
          <li>
            <a href="https://www.linkedin.com/company/cancer-research-uk/">
              <img src="/sites/all/themes/custom/cruk/images/social_icons/linkedin_icon.svg" width="40" height="40" alt="Connect with Cancer Research UK on LinkedIn">
            </a>
          </li>
          <li>
            <a href="https://www.youtube.com/user/cancerresearchuk">
              <img src="/sites/all/themes/custom/cruk/images/social_icons/youtube_icon.svg" width="40" height="40" alt="Subscribe to Cancer Research UK on YouTube">
            </a>
          </li>
        </ul>
      </div>
    </div>

    <div class="footer-links">
      <div class="footer-links__list--horizontal">
        <ul class="links"><li class="0 first"><a href="/about-cancer/about-our-information">About our information</a></li>
<li class="1"><a href="/about-us/utilities/terms-and-conditions">Terms and conditions</a></li>
<li class="2"><a href="/about-us/utilities/privacy-statement">Privacy</a></li>
<li class="3"><a href="/modern-slavery-transparency-statement">Modern Slavery Statement</a></li>
<li class="4"><a href="/about-us/utilities/cookies-policy">Cookies</a></li>
<li class="5"><a href="/about-us/utilities/accessibility">Accessibility</a></li>
<li class="6 last"><a href="/sitemap">Sitemap</a></li>
</ul>      </div>
    </div>

    <div id="awards" class="footer-secondary-content">
      <a href="https://www.fundraisingregulator.org.uk/"><img src="/sites/all/themes/custom/cruk/images/fund-reg.svg" alt="Registered with Fundraising Regulator (logo)" width="165" height="52"></a>
    </div>

    <address class="footer-secondary-content">Cancer Research UK is a registered charity in England and Wales (1089464), Scotland (SC041666), the Isle of Man (1103) and Jersey (247). A company limited by guarantee. Registered company in England and Wales (4325234) and the Isle of Man (5713F). Registered address: 2 Redman Place, London, E20 1JQ.</address>
  </div>
</footer>
<script src="https://www.cancerresearchuk.org/sites/all/libraries/modernizr/modernizr-3.3.1.js?"></script>
<script src="https://www.cancerresearchuk.org/sites/all/modules/contrib/jquery_update/replace/jquery/2.1/jquery.min.js?v=2.1.4"></script>
<script>jQuery.migrateMute=true;jQuery.migrateTrace=false;</script>
<script src="https://www.cancerresearchuk.org/sites/all/modules/contrib/jquery_update/replace/jquery-migrate/1/jquery-migrate.min.js?v=1"></script>
<script src="https://www.cancerresearchuk.org/misc/jquery-extend-3.4.0.js?v=2.1.4"></script>
<script src="https://www.cancerresearchuk.org/misc/jquery-html-prefilter-3.5.0-backport.js?v=2.1.4"></script>
<script src="https://www.cancerresearchuk.org/misc/jquery.once.js?v=1.2"></script>
<script src="https://www.cancerresearchuk.org/misc/drupal.js?"></script>
<script src="https://www.cancerresearchuk.org/sites/all/modules/contrib/jquery_update/replace/ui/ui/minified/jquery.ui.core.min.js?v=1.10.2"></script>
<script src="https://www.cancerresearchuk.org/sites/all/modules/contrib/jquery_update/replace/ui/ui/minified/jquery.ui.widget.min.js?v=1.10.2"></script>
<script src="https://www.cancerresearchuk.org/sites/all/modules/contrib/jquery_update/replace/ui/external/jquery.cookie.js?v=67fb34f6a866c40d0570"></script>
<script src="https://www.cancerresearchuk.org/sites/all/modules/contrib/jquery_update/replace/ui/ui/minified/jquery.ui.position.min.js?v=1.10.2"></script>
<script src="https://www.cancerresearchuk.org/misc/ui/jquery.ui.position-1.13.0-backport.js?v=1.10.2"></script>
<script src="https://www.cancerresearchuk.org/misc/ajax.js?v=7.103"></script>
<script src="https://www.cancerresearchuk.org/sites/all/modules/contrib/jquery_update/js/jquery_update.js?v=0.0.1"></script>
<script src="https://www.cancerresearchuk.org/sites/all/modules/custom/clientside_validation_rule_pword_match/js/clientside_validation_rule_pword_match.js?"></script>
<script src="https://www.cancerresearchuk.org/sites/all/modules/custom/cruk_donate/js/cruk_donate.js?"></script>
<script src="https://www.cancerresearchuk.org/sites/all/modules/custom/cruk_gc_timeline/js/jquery.kinetic.min.js?"></script>
<script src="https://www.cancerresearchuk.org/sites/all/modules/custom/cruk_gc_timeline/js/timeline.js?"></script>
<script src="https://www.cancerresearchuk.org/sites/all/modules/contrib/entityreference/js/entityreference.js?"></script>
<script src="https://www.cancerresearchuk.org/sites/all/modules/contrib/geofield_gmap/geofield_gmap.js?"></script>
<script src="https://www.cancerresearchuk.org/sites/all/modules/contrib/resp_img/resp_img.js?" class="optanon-category-fun cruk-onetrust-blocked-scripts"></script>
<script src="https://www.cancerresearchuk.org/sites/all/modules/custom/cruk_core_info/js/cruk_core_info.js?"></script>
<script src="https://www.cancerresearchuk.org/sites/all/modules/custom/cruk_core_info/js/clipboard.min.js?"></script>
<script src="https://www.cancerresearchuk.org/sites/all/modules/custom/cruk_image_gallery/js/slick.min.js?"></script>
<script src="https://www.cancerresearchuk.org/sites/all/modules/custom/cruk_shine_night_walks/js/select-styling.js?"></script>
<script src="https://www.cancerresearchuk.org/sites/all/modules/custom/cruk_config_fieldable_panels/js/cruk_config_fieldable_panels_geolocation.js?"></script>
<script src="https://www.cancerresearchuk.org/sites/all/modules/custom/cruk_donate/selectmenu/jquery.ui.selectmenu.js?v=1.3.0"></script>
<script src="https://www.cancerresearchuk.org/misc/progress.js?v=7.103"></script>
<script src="https://www.cancerresearchuk.org/sites/all/modules/custom/cruk_onetrust/js/crukOneTrustPlaceholder.js?"></script>
<script src="https://www.cancerresearchuk.org/sites/all/modules/custom/cruk_onetrust/js/crukOneTrustDynatrace.js?"></script>
<script src="https://www.cancerresearchuk.org/sites/all/modules/custom/cruk_onetrust/js/crukOneTrustRefreshBlockedScripts.js?"></script>
<script src="https://platform.twitter.com/widgets.js" class="optanon-category-tar cruk-onetrust-blocked-scripts"></script>
<script src="https://www.cancerresearchuk.org/sites/all/modules/contrib/extlink/js/extlink.js?"></script>
<script src="https://www.cancerresearchuk.org/sites/all/themes/custom/cruk/scripts/vendor/bootstrap/bootstrap/collapse.js?"></script>
<script src="https://www.cancerresearchuk.org/sites/all/themes/custom/cruk/scripts/vendor/bootstrap/bootstrap/dropdown.js?"></script>
<script src="https://www.cancerresearchuk.org/sites/all/themes/custom/cruk/scripts/vendor/bootstrap/bootstrap/transition.js?"></script>
<script src="https://www.cancerresearchuk.org/sites/all/themes/custom/cruk/scripts/vendor/bootstrap/bootstrap/carousel.js?"></script>
<script src="https://www.cancerresearchuk.org/sites/all/themes/custom/cruk/scripts/vendor/packery.pkgd.min.js?"></script>
<script src="https://www.cancerresearchuk.org/sites/all/themes/custom/cruk/scripts/vendor/slick.min.js?"></script>
<script src="https://www.cancerresearchuk.org/sites/all/themes/custom/cruk/scripts/vendor/pure.min.js?"></script>
<script src="https://www.cancerresearchuk.org/sites/all/themes/custom/cruk/scripts/vendor/jquery.mobile.custom.min.js?"></script>
<script src="https://www.cancerresearchuk.org/sites/all/themes/custom/cruk/scripts/vendor/media.match.min.js?"></script>
<script src="https://www.cancerresearchuk.org/sites/all/themes/custom/cruk/scripts/vendor/enquire.js?"></script>
<script src="https://www.cancerresearchuk.org/sites/all/themes/custom/cruk/scripts/vendor/ios-orientationchange-fix.js?"></script>
<script src="https://www.cancerresearchuk.org/sites/all/themes/custom/cruk/scripts/console.js?"></script>
<script src="https://www.cancerresearchuk.org/sites/all/themes/custom/cruk/scripts/tabs_to_accordion.js?"></script>
<script src="https://www.cancerresearchuk.org/sites/all/themes/custom/cruk/scripts/cruk-accordion.js?"></script>
<script src="https://www.cancerresearchuk.org/sites/all/themes/custom/cruk/scripts/jquery.megamenu.js?"></script>
<script src="https://www.cancerresearchuk.org/sites/all/themes/custom/cruk/scripts/script.js?"></script>
<script src="https://www.cancerresearchuk.org/sites/all/themes/custom/cruk/scripts/jquery.mobile-rebrand.js?"></script>
<script src="https://www.cancerresearchuk.org/sites/all/themes/custom/cruk/scripts/interactive_timeline.js?"></script>
<script>jQuery.extend(Drupal.settings, {"basePath":"\/","pathPrefix":"","setHasJsCookie":0,"ajaxPageState":{"theme":"cruk","theme_token":"bAM8BEYUuDEzikMwXfYk36vVsTNAJ-tQMm2A0m6V8YY","jquery_version":"2.1","js":{"sites\/all\/modules\/custom\/cruk_image_gallery\/js\/cruk_image_gallery.js":1,"0":1,"sites\/all\/libraries\/modernizr\/modernizr-3.3.1.js":1,"sites\/all\/modules\/contrib\/jquery_update\/replace\/jquery\/2.1\/jquery.min.js":1,"1":1,"sites\/all\/modules\/contrib\/jquery_update\/replace\/jquery-migrate\/1\/jquery-migrate.min.js":1,"misc\/jquery-extend-3.4.0.js":1,"misc\/jquery-html-prefilter-3.5.0-backport.js":1,"misc\/jquery.once.js":1,"misc\/drupal.js":1,"sites\/all\/modules\/contrib\/jquery_update\/replace\/ui\/ui\/minified\/jquery.ui.core.min.js":1,"sites\/all\/modules\/contrib\/jquery_update\/replace\/ui\/ui\/minified\/jquery.ui.widget.min.js":1,"sites\/all\/modules\/contrib\/jquery_update\/replace\/ui\/external\/jquery.cookie.js":1,"sites\/all\/modules\/contrib\/jquery_update\/replace\/ui\/ui\/minified\/jquery.ui.position.min.js":1,"misc\/ui\/jquery.ui.position-1.13.0-backport.js":1,"misc\/ajax.js":1,"sites\/all\/modules\/contrib\/jquery_update\/js\/jquery_update.js":1,"sites\/all\/modules\/custom\/clientside_validation_rule_pword_match\/js\/clientside_validation_rule_pword_match.js":1,"sites\/all\/modules\/custom\/cruk_donate\/js\/cruk_donate.js":1,"sites\/all\/modules\/custom\/cruk_gc_timeline\/js\/jquery.kinetic.min.js":1,"sites\/all\/modules\/custom\/cruk_gc_timeline\/js\/timeline.js":1,"sites\/all\/modules\/contrib\/entityreference\/js\/entityreference.js":1,"sites\/all\/modules\/contrib\/geofield_gmap\/geofield_gmap.js":1,"sites\/all\/modules\/contrib\/resp_img\/resp_img.js":1,"sites\/all\/modules\/custom\/cruk_core_info\/js\/cruk_core_info.js":1,"sites\/all\/modules\/custom\/cruk_core_info\/js\/clipboard.min.js":1,"sites\/all\/modules\/custom\/cruk_image_gallery\/js\/slick.min.js":1,"sites\/all\/modules\/custom\/cruk_shine_night_walks\/js\/select-styling.js":1,"sites\/all\/modules\/custom\/cruk_config_fieldable_panels\/js\/cruk_config_fieldable_panels_geolocation.js":1,"sites\/all\/modules\/custom\/cruk_donate\/selectmenu\/jquery.ui.selectmenu.js":1,"misc\/progress.js":1,"sites\/all\/modules\/custom\/cruk_onetrust\/js\/crukOneTrustPlaceholder.js":1,"sites\/all\/modules\/custom\/cruk_onetrust\/js\/crukOneTrustDynatrace.js":1,"sites\/all\/modules\/custom\/cruk_onetrust\/js\/crukOneTrustRefreshBlockedScripts.js":1,"https:\/\/platform.twitter.com\/widgets.js":1,"sites\/all\/modules\/contrib\/extlink\/js\/extlink.js":1,"sites\/all\/themes\/custom\/cruk\/scripts\/vendor\/bootstrap\/bootstrap\/collapse.js":1,"sites\/all\/themes\/custom\/cruk\/scripts\/vendor\/bootstrap\/bootstrap\/dropdown.js":1,"sites\/all\/themes\/custom\/cruk\/scripts\/vendor\/bootstrap\/bootstrap\/transition.js":1,"sites\/all\/themes\/custom\/cruk\/scripts\/vendor\/bootstrap\/bootstrap\/carousel.js":1,"sites\/all\/themes\/custom\/cruk\/scripts\/vendor\/packery.pkgd.min.js":1,"sites\/all\/themes\/custom\/cruk\/scripts\/vendor\/slick.min.js":1,"sites\/all\/themes\/custom\/cruk\/scripts\/vendor\/pure.min.js":1,"sites\/all\/themes\/custom\/cruk\/scripts\/vendor\/jquery.mobile.custom.min.js":1,"sites\/all\/themes\/custom\/cruk\/scripts\/vendor\/media.match.min.js":1,"sites\/all\/themes\/custom\/cruk\/scripts\/vendor\/enquire.js":1,"sites\/all\/themes\/custom\/cruk\/scripts\/vendor\/ios-orientationchange-fix.js":1,"sites\/all\/themes\/custom\/cruk\/scripts\/console.js":1,"sites\/all\/themes\/custom\/cruk\/scripts\/tabs_to_accordion.js":1,"sites\/all\/themes\/custom\/cruk\/scripts\/cruk-accordion.js":1,"sites\/all\/themes\/custom\/cruk\/scripts\/jquery.megamenu.js":1,"sites\/all\/themes\/custom\/cruk\/scripts\/script.js":1,"sites\/all\/themes\/custom\/cruk\/scripts\/jquery.mobile-rebrand.js":1,"sites\/all\/themes\/custom\/cruk\/scripts\/interactive_timeline.js":1},"css":{"modules\/system\/system.base.css":1,"modules\/system\/system.menus.css":1,"modules\/system\/system.messages.css":1,"modules\/system\/system.theme.css":1,"0":1,"misc\/ui\/jquery.ui.core.css":1,"misc\/ui\/jquery.ui.theme.css":1,"modules\/aggregator\/aggregator.css":1,"sites\/all\/modules\/custom\/cruk_gc_timeline\/css\/grand_challenge_timeline.css":1,"modules\/field\/theme\/field.css":1,"sites\/all\/modules\/contrib\/geofield_gmap\/geofield_gmap.css":1,"modules\/node\/node.css":1,"modules\/search\/search.css":1,"modules\/user\/user.css":1,"sites\/all\/modules\/contrib\/extlink\/css\/extlink.css":1,"sites\/all\/modules\/contrib\/views\/css\/views.css":1,"sites\/all\/modules\/contrib\/ckeditor\/css\/ckeditor.css":1,"sites\/all\/modules\/contrib\/ctools\/css\/ctools.css":1,"sites\/all\/modules\/contrib\/panels\/css\/panels.css":1,"sites\/all\/themes\/custom\/cruk_grand_challenge\/layouts\/grand_challenge_winners\/grand_challenge_winners.css":1,"sites\/all\/modules\/custom\/cruk_donate\/selectmenu\/jquery.ui.selectmenu.css":1,"sites\/all\/modules\/contrib\/node_embed\/plugins\/node_embed\/node_embed.css":1,"sites\/all\/themes\/contrib\/mothership\/mothership\/css\/reset.css":1,"sites\/all\/themes\/contrib\/mothership\/mothership\/css\/reset-html5.css":1,"sites\/all\/themes\/contrib\/mothership\/mothership\/css\/mothership-default.css":1,"sites\/all\/themes\/contrib\/mothership\/mothership\/css\/mothership.css":1,"sites\/all\/themes\/custom\/cruk\/css\/tabs_to_accordion.css":1,"sites\/all\/themes\/custom\/cruk\/css\/style.css":1,"sites\/all\/themes\/custom\/cruk\/css\/cruk.menus.css":1,"sites\/all\/themes\/custom\/cruk\/css\/mobile.menu.css":1,"sites\/all\/themes\/custom\/cruk\/css\/slick.css":1,"sites\/all\/themes\/custom\/cruk\/css\/content_panel.css":1,"sites\/all\/themes\/custom\/cruk\/css\/scroller.css":1,"sites\/all\/themes\/custom\/cruk\/normalize.css":1,"sites\/all\/themes\/custom\/cruk\/reset.css":1,"sites\/all\/themes\/custom\/cruk\/reset-html5.css":1,"sites\/all\/themes\/custom\/cruk\/mothership.css":1,"sites\/all\/themes\/custom\/cruk\/mothership-default.css":1,"sites\/all\/themes\/custom\/cruk\/mothership-devel-mediaqueries.css":1,"sites\/all\/themes\/custom\/cruk\/css\/print.css":1,"public:\/\/css_injector\/css_injector_31.css":1,"public:\/\/css_injector\/css_injector_131.css":1,"public:\/\/css_injector\/css_injector_156.css":1,"public:\/\/css_injector\/css_injector_196.css":1,"public:\/\/css_injector\/css_injector_201.css":1,"public:\/\/css_injector\/css_injector_206.css":1,"public:\/\/css_injector\/css_injector_211.css":1,"public:\/\/css_injector\/css_injector_226.css":1,"public:\/\/css_injector\/css_injector_241.css":1,"public:\/\/css_injector\/css_injector_251.css":1,"public:\/\/css_injector\/css_injector_261.css":1,"public:\/\/css_injector\/css_injector_276.css":1,"public:\/\/css_injector\/css_injector_281.css":1,"public:\/\/css_injector\/css_injector_291.css":1,"public:\/\/css_injector\/css_injector_296.css":1,"public:\/\/css_injector\/css_injector_306.css":1,"public:\/\/css_injector\/css_injector_361.css":1,"public:\/\/css_injector\/css_injector_371.css":1,"public:\/\/css_injector\/css_injector_376.css":1,"public:\/\/css_injector\/css_injector_426.css":1,"public:\/\/css_injector\/css_injector_441.css":1,"public:\/\/css_injector\/css_injector_466.css":1,"public:\/\/css_injector\/css_injector_471.css":1,"public:\/\/css_injector\/css_injector_516.css":1,"public:\/\/css_injector\/css_injector_561.css":1,"public:\/\/css_injector\/css_injector_576.css":1,"public:\/\/css_injector\/css_injector_581.css":1,"public:\/\/css_injector\/css_injector_601.css":1,"public:\/\/css_injector\/css_injector_610.css":1,"public:\/\/css_injector\/css_injector_616.css":1,"public:\/\/css_injector\/css_injector_617.css":1,"public:\/\/css_injector\/css_injector_619.css":1,"public:\/\/css_injector\/css_injector_620.css":1}},"respImg":{"default_suffix":"_breakpoint_one","current_suffix":false,"forceRedirect":"0","forceResize":"1","reloadOnResize":"0","useDevicePixelRatio":1,"suffixes":{"_breakpoint_two":640,"_breakpoint_three":480,"_breakpoint_four":320,"_breakpoint_one":1}},"extlink":{"extTarget":"_blank","extClass":"external","extLabel":"(link is external)","extImgClass":0,"extIconPlacement":0,"extSubdomains":1,"extExclude":"(twitter\\.com|facebook\\.com|addthis\\.com|cancerresearchuk\\.org|cruk\\.org|cruk01)","extInclude":"https:\/\/www.cancerresearchuk.org\/(sites\/default\/files\/*)","extCssExclude":".social-link,.ignore-external,.navbar,.cruk-nav,.footer-social,.about-cancer-footer-icons,.pane-node-field-landing-key-message","extCssExplicit":"","extAlert":0,"extAlertText":"This link will take you to an external web site.","mailtoClass":0,"mailtoLabel":"(link sends e-mail)","extUseFontAwesome":0}});</script>

      
<script src="https://www.cancerresearchuk.org/sites/all/modules/custom/cruk_image_gallery/js/cruk_image_gallery.js?"></script>
<script>
  function OptanonWrapper() {

    crukOneTrustUpdatePlaceholders();

    crukOneTrustUpdateDynatrace();

    crukOneTrustRefreshBlockedScripts();
}</script>
</body>
</html>
